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Abstract 
The subject of this thesis is multicolor bioluminescence analysis and how it can 
provide new tools for drug discovery and development. Different applications of 
bioluminescence imaging using multicolor luciferases are defined in the first part of 
the thesis while in the second part the development of multicolor cell based assay is 
shown. Both in vivo and in vitro methods are useful in pharmacological research: cell-
based assay are usually employed in high-throughput screening while 
bioluminescence based mouse models are useful both for target discovery and 
validation and for preclinical studies of drug efficiency, drug release and 
biodistribution. The advantage of using luciferases with different emission spectrum, 
so that the bioluminescence emission peak can extend range between the yellow to 
the red red region of the UV/visible spectrum, is that multiple analysis can be 
performed and  information can be obtained in one analytical session. Moreover 
small animal bioluminescence imaging (BLI) is a technique that allows the collection 
of data with no need for animal sacrifices and permit to perform longitudinal studies 
on the same animal. 
In Chapter 2 the potential of red-emitting firefly luciferase mutants to enhance 
bioluminescence imaging experiments is demonstrated. By establishing two mouse 
cancer models employing the Ppy-RE-TS mutant ( max =620nm) or WT luciferase 
(commonly used in bioluminescence imaging studies in vivo), the superior 
characteristics of the red enzyme for in vivo imaging have been pointed out. That is 
because the optimal window for in vivo imaging is after 600nm where the tissue 
absorption (mostly due to haemoglobin) is minimal. 
In Chapter 3 an optimized version of the red luciferase named above, Ppy Re8, has 
been shown to be useful in imaging gastric emptying in mouse models. Non -
pathogenic bacterial expressing the luciferases were administered by gavages to the 
animals: the bacteria acted as luminescent beads and mixed to the gastric contents. 
Images of the mice were taken at different time points and used to derive curves for 
the gastric emptying process. This model demonstrated to be useful for the 
evaluation of the physiological process and can be employed for the development of 
new drugs acting of gastric motility and in particular for the study of side effects of 
drugs. Moreover mice in different pathological conditions can be investigated for 
physiopathological studies of the gastric emptying process in drug efficacy studies. 
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In Chapter 4 Ppy-RE8 enzyme, which is codon optimized for mammalian expression 
in combination with the green click beetle luciferase, CBG99 for in vitro and in vivo 
dual color imaging applications has been investigated. The  comparison of the 
spectral characteristics of this dual expression strategy, using a single substrate D-
luciferin, in human embryonic kidney cells (HEK293) utilizing different proportions of 
cells expressing each luciferase, showed the potential of this strategy to follow two 
distinct events in real time and in vivo. 
In Chapter 5 and 6. A new luciferase isolated from L. italica and thermostable red- 
and green-emitting mutants obtained by random and site-directed mutagenesis. were 
tested for their suitability for multicolor assays. A mammalian triple-color reporter 
model system was then developed using a green-emitting wild-type P. pyralis 
luciferase, a red thermostable mutant of L. italica luciferase and a secreted Gaussia 
princeps luciferase (GLuc) to monitor the two main pathways of bile acid 
biosynthesis. The two firefly luciferases were used to monitor cholesterol 7-α 
hydroxylase and sterol 27- hydroxylase, while secreted constitutively expressed 
GLuc was used as an internal vitality control. By treating the cells with 
chenodeoxycholic acid it was possible to obtain dose-dependent inhibitions of the 
two specific signals together with a constant production of GLuc, which allowed for a 
dynamic evaluation of the metabolic activity of the cells. The reported assays were 
the first triple-color mammalian reporter assay that combines secreted and non-
secreted luciferases requiring different substrates, thus avoiding reciprocal 
interference between different BL signals. This approach is demonstrated to suitable 
for high content analysis of gene transcription in living cells to shorten the time for 
screening assays, increasing throughput and cost-effectiveness. Multiple assays can 
be developed using this strategy fuelling the drug discovery process. 
In vivo Bioluminescence imaging has known a rapid progress since its first 
application no more than 15 years ago. It is becoming an indispensable tool in 
pharmacological research. Nowadays researchers put a lot of efforts into 
improvements of instrumentation for light detection and analysis and into the 
improvements of the bioluminescent probes available. The application of the 
technology is booming and the author of this thesis is sure that multicolor 
bioluminescence imaging will boom and improve as well leading to new discoveries 
in life science, medicine and pharmacological research. 
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Introduction 
 
Bioluminescence 
The term Bioluminescence is generally used for the definition every kind of 
Chemiluminescence produced by a specific biochemical reaction occuring in a living 
organism. Bioluminescence reactions involve an enzyme “luciferase” and a substrate 
“luciferin” and present high quantum yield. The latter is a very important parameter: in 
theory, every molecule that reacts could produce a photon but only a fraction of them 
brings to the release of photons. The quantum yield of a bio/chemiluminescence 
reaction is defined by  following the equation: 
 
bio/chemiluminescence = emitted photons/ n° reacting molecules 
 
For the luciferase/luciferin reaction from Photinus pyralis firefly the value is higher 
compared to those of chemiluminescence reaction and it is  0.441.  
One of the unique features of bioluminescence is that, unlike other forms of light, it is 
“cold light”. In fact, bioluminescent light is produced with very little heat radiation. 
The modern study of bioluminescence beagan when Dubois demonstrated the first 
example of a luciferin/luciferase reaction in 1885 and he concluded that an enzyme 
and a specific, relatively heat stable substance, which he designated "luciferine" were  
necessary for the light-emitting reaction. Following the discovery the person who 
coniated the term “bioluminescence” and made important studies of the phenomenon 
was E. Newton Harvey (1887-1959) of Princeton University. Harvey traveled widely 
and studied the bioluminescence of a great variety of luminous organisms, producing 
over 300 publications. His book Bioluminescence published in 1952 is considered the 
bible of bioluminescence. In the 20th century many other scientists gave outstanding 
contribution to the description and the application of bioluminescence in life sciences 
and medicine: among them Stanley P.E., Kricka L, Mc Capra F. ,Hastings J. W., Mc 
Elroy W. and Shimomura O. Nowadays the book “Bioluminescence” published in 
2008 by the nobel prize O.Shimomura is considered the new bible2. 
Bioluminescence can serve more purposes within a single organism, both offensive 
such as to lure, confuse or illuminate prey and defensive, such as sturtle, burglar 
alarm or misdirection of predators as well as mate attraction and recognition. In the 
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marine environment the predominant bioluminescence colour is blue (around 470nm) 
because light at this wavelength transmits furthest in water so many organism 
evolved to be sensitive only to blue light, lacking visual pigments for longer or shorter 
wavelengths. In the terrestrial environment, green is the predominant 
bioluminescence colour as a result of an ecological adaptation of bioluminescence to 
the photic environment 3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Wavelenghts emission of tereestrial and marine organisms. 
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Bioluminescent systems 
 
Firefly luciferases and mutants 
Luciferases from fireflies family  are the most studied and  the most commonly used. 
The luciferin-luciferase reaction of fireflies was first demonstrated by Harvey (1917), 
although the light observed was weak and shortlasting. Thirty years after Harvey's 
discovery, McElroy (1947) made a crucial breakthrough in the study of firefly 
bioluminescence. He found that the light-emitting reaction requires ATP as a 
cofactor. In 1949, McElroy and Strehler found that the luminescence reaction 
requires Mg2+ in addition to luciferin, luciferase and ATP. The active luciferin was 
found to be in the D-form while the L-form is practically inactive. Luciferase from 
Photinus pyralis belongs to the Lampyridae family that are carachterized by sexual 
dimorfism. Though the females of some species are similar in appearance to males, 
larviform females are found in many other firefly species. These females can often be 
distinguished from the larvae only because they have compound eyes. In the major 
part of the species male are 1cm long and have wings. The organ for light emission 
is in the terminal part of the abdomen. In some species this organ is bigger in male 
individuals but generally both sexes can emit light. 
  
 
 
 
 
 
 
 
Figure 2: Photinus pyralis 
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The reaction mechanism is not fully understood yet and it consists in the rapid 
conversion of the substrate luciferin in luciferyl-adenilate linked to the enzyme in 
presence of Mg2+ and  ATP. Pyrophospate is released in this phase then the 
combination with oxygen lead to the formation of the luciferase-oxyluciferin- adenilate 
complex and to the elimination of CO2. The complex is in an “excited state” and it 
returns to the fundamental state by emitting photons. At the end the complex is 
dissociated in luciferase, AMP and oxyluciferin (Figure 3) 
 
 
Figure 3: Mechanism of reaction of firefly luciferase and D- luciferin 
Since luciferase demonstrated a greater affinity for the oxyluciferin compared to 
reduced luciferin, high concentration of substrate may inhibit the reaction with a 
competitive mechanism so that the last step of the reaction result to be the limiting 
one4. Recent studies have demonstrated that in nature Luciferase regenerating 
enzyme (LRE), peptides of 38 kDa, can convert oxyluciferin in a form that in 
presence of D-cystein can be converted in luciferin (Figure 4)5,6 . The reactivation of 
the enzyme luciferase, instead, is operated by the coenzyme A that removes the 
adenil-oxyluciferin from the surface of the enzyme7. 
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Figure 4. Proposed mechanism of luciferin regeneration 
Luciferase from  P. pyralis is an enzyme of 62 kDa and with a maximum of emission 
at 562nm at 25°C and pH 7.8. The enzyme presents two polypeptididic subunit with 
identical amminoacidic sequences but only one is responsible for bioluminescence 
activity. The active site create san hydrophobic enviroment with two sulfidric groups 
essential for the catalytic activity8. In the mechanism proposed by Branchini et al. the 
red emission (max 615 nm), observed at pH 6.0 is produced by the chetonic form 
while the yellow-green emission (max 560 nm) at pH 8.0 is produced by the enolate 
anion form of the excited oxyluciferin9 (Figure 5,6). 
 
Figure 5.  Keto-enolTautomerization of  D-luciferin 
In nature, beetle luciferases have different emission colors: one of the proposed 
hypotesis is that the charge delocalization in the excited state cause the different 
wavelenght emissions. Recently other hypotesis have been proposed and the real 
cause of the different emission colors is still controversial1,10. In order to improve 
characteristics for analytical application luciferase from Photinus pyralis underwent 
random and site specific mutagenesis. The group of Prof. B. Branchini generated two 
variants: Ppy GR-TS and  Ppy RE-TS that have a maximum emission wavelength 
respectively 546nm and 610nm. The former is mutated on the residues Val241Ile, 
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Gly246Ala and Phe250 Ser, while the latter on the residue Ser284Thr, which is 
responsible for the red emission, and  Thr214Ala, Ala215Leu, Ile232Ala, Phe295Leu 
and Glu354Lys for increasing stability at 37°C11. Moreover additional changes in the 
amminoacidic sequence have been apported : Arg330Gly e Glu354Lys  generated  
the Ppy RE8 form, with a maximum  emission wavelength at 617nm. Such a red shift 
causes a loss of thermostability and activity of the enzyme so that mutations in the 
amminoacidic residues Phe465Arg e Ile351Val were necessary. Moreover the CDS 
sequence of Ppy RE8 enzyme has been  codon optimized for mammalian 
expression, by eliminating repeats, local hairpin and criptic splicing sites. Ppy RE8 
has 8 different amminoacid compared to the wild type enzyme and its thermostability 
rends it useful for cell based assay and in vivo imaging12.  
 
Figure 6 . Mechanism of reaction with different hypotesis on the variation of colour emission. 
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Click beetle and railroad worm 
Click beetle luciferases 
The genus Pyrophorus belongs to the Eleteridae family and includes 26 
bioluminescent species amongst Caribbeans, Central anb south America. The 
biolumienscence reaction is similar to that of coleoptera and requires the same 
substrate and cofactors even is the ventral light emission is continuos13. They 
generally eat pollen and little insects like aphids. They lay eggs that are luminescent 
as larvae that growth up slowly (even years) Pyrophorus plagiophthalamus, the 
lamaica click beetle present a strong polymorphism in the color of light emission It 
has two different light organs: a ventral one that emits light in the yellow green (558-
562nm) and orange (591-595nm) and two dorsal organs that emit green (544-
548nm) and yellow-grren (557-562nm) (figure 7).  
 
Figura 7: Pyrophorus plagiophthalamus emits green light form the dorsal organ (A) and 
orange from the ventral ones (B)  
Four genes were cloned and mutagenized from this insect that differs one another for 
emission spectrum and intensity porperties.  
 
 
 
 
 
 
Figure 8: Emission spectra and intensities of Pyrophorus plagiophthalamus mutants(biblio) 
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Thermostable mutants emits in the red region of the Uv/visible spectrum  as CBRLuc 
or in the green region as CBG68luc and  CBG99luc. In every sequence the 
peroxisome targeting sequence has been removed to obtain a citoplasmatic 
localization of the espresse enzyme14,15. CBG99Luc has a peak of emission at 537 
nm while CBRluc at 615 nm at the temperature of 25°C. The most important 
characteristics is that the emission spectrum of these enzyme is not influenced by 
variation in the pH like fireflies enzymes(Figure 8). 
Railroad worm 
The railroad worm Phrixothrix is well known for displaying two different colors of 
luminescence from a single organism. This genus is widely distributed in Central and 
South America and belongs to the family of Phengodidae (Figure 9).The larva of 
Phrixothrix (and also the adult female) emits a greenish yellow light (max 535-565 
nm) from 11 pairs of luminous organs on the posterior lateral margins of the second 
to the ninth segment, and a red light (max 600-620 nm) from the luminous area on 
the head. The adult male is a typical beetle and does not show a noticeable 
luminescence. The bioluminescence systems of these phengodids were essentially 
the same as that of the fireflies, involving the same luciferin (firefly luciferin), ATP and 
Mg +. Their emission maxima of luminescence from the lateral and head organs are 
in the ranges of 535-592nm and 562-638 nm, respectively. The color differences are 
probably due to the presence of luciferase isoenzymes (Mr about 60,000) according 
to the authors16. Viviani et al. (1999) cloned the luciferases from the lateral light 
organs of Phrixothrix vivianii (emission Xmax 542 nm) and the head light organs of 
Phrixothrix hirtus (emission Amax 628 nm). Recently, the latter enzyme has been 
mutated  for improving stability and activity17. 
 
Figure 9. Railroad worm Phrixothrix hirtus 
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Renilla and Gaussia lucifarases 
Luciferase from Renilla reniformis  
Renilla reniformis, is a marine coral belonging to the family of Renilladae, class of 
Anthozoa (Figure 10). Renilla luciferase is a monomeric photprotein with a molecular 
wheight of 36Kd and shares the conserved catalytic triad of residues employed by 
the dehalogenases, as confirmed by its crystallographic data18. The enzymatic 
reaction does not require ATP and its substrate coelenterazine has a good 
penetration through cell membrane. The use of  Renilla luciferase as reporter gene 
involves its application in combination with fireflies luciferase for dual reporter assay. 
Coelenterazine, shown in figure 10, is the common substrate for Renilla luciferase, 
apoequorin, gaussia and metridia luciferases that have been recently cloned. The 
luciferase/coelenterazine reaction produces mostly blue light: peak of emission of 
Renilla luciferase is 480nm. In 2007 A.Loening et al. generated by random and site 
directed mutagenesis Renilla variants with different emission spectrum and increased 
activity and stability19.Rluc8 shows an emission peak at 535nm has an half life of 50h 
and an activity of 1.4 fold higher than the native enzyme. Consequently Rluc8 
improved the sensitivity of the detection in both in vitro and in vivo applications. 
Moreover they generated a new red shifted mutant Rluc7-535 with an half life 
comparable to the one of the native enzyme (6.5H) in order to achieve sensitivity in 
transient gene expression analysis20. Renilla luciferase has been widely applied as 
luminescent donor in bioluminescence resonance Enrgy Transfer method for studing 
protein-protein interaction21. 
 
 
 
Figure 10. .Renilla reniformis and Coelenterazine structure 
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Luciferase from Gaussia princeps 
Gaussia luciferase (Gluc) is a novel secreted luciferase, cloned from the copepod 
Gaussia princeps, that catalyzes the oxidation of the small molecule coelenterazine 
to produce light (Figure 11). Unlike the firefly luciferase systems, these 
coelenterazine-utilizing luciferases do not require accessory high-energy molecules 
such as ATP, simplifying their use in a number of reporter applications22,23. This 
luciferase catalyzes the oxidation of the substrate coelenterazine in a reaction that 
emits light (λem = 470 nm),and has considerable advantages over other reporter 
genes. Thanks to its pH resistance in a range from 3 to 11 with an optimum at pH 
7.8, and its good thermostability (up to 60°C), GLuc is an attractive tool in report 
gene assays or as an enzyme label for bioanalytical applications, particularly for the 
development of bioluminescence (BL) cell based assays and for BL imaging animal 
models. GLuc is the smallest luciferase isolated to date (19.9 KDa) and this small 
size is a crucial factor for the construction of fusion proteins to avoid steric hindrance. 
Moreover since Gluc, when expressed into mammalian cells, is secreted into the 
culture medium the BL measurements are performed by simply addition of 
coelenterazine in culture medium, without the need for cell lysis. 
 
 
Figure 11. Gaussia princeps copepod 
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Bioanalytical application of bioluminescence 
The typical bioanalytical applications of bioluminescence (BL) proteins include the 
investigation of protein–protein interactions, protein conformational changes, protein 
phosphorylation, second-messengers expression, and, in general, the study of gene 
expression and gene regulation in vitro and in vivo
24,25
. The expression of a BL 
protein can be put under the control of tissue-specific regulatory elements allowing 
non-invasive imaging of physiological and pathological processes like differentiation, 
apoptosis, tumor progression, and inflammation, even in a 3D fashion by means of 
BL tomography, which allows 3D BL source reconstruction26. Since BL proteins can 
be detected down to very low levels, they allow ultrasensitive detection of the target 
analytes and monitoring of the physiological phenomena under investigation. These 
BL features, associated to instrumental and technical advancements in 
miniaturization, enable the analysis of small-volume samples, which leads to the 
development of miniaturized and high-throughput assays. 
Bioluminescence imaging in vivo 
Bioluminescence in vivo imaging The commercial availability of ultrasensitive imaging 
systems based on charge-coupled device (CCD) technology together with the high 
number of BL probes greatly expanded the use of BL in a variety of imaging formats 
and techniques, spanning from Petri dishes to microtiter plates and to whole-animal 
imaging. Usually the spatial resolution of the BL signal is in the order of 100–200 µm 
and may reach 0.4 µm when in combination with optical microscopy, thus similar to 
that achieved with conventional light imaging.27 Optical imaging makes it possible to 
reveal cellular and molecular events in real time, thus tracking biological processes in 
living animals with a significant reduction in the number of animals needed. Diverse 
imaging strategies have been developed and successfully employed to study tumour 
progression and metastasis, infectious pathways of viruses, gene expression 
patterns, graft-versus-host diseases.28-31 Thanks to high sensitivity and the 
availability of new red and BL proteins emitting in the near infra-red (whose emission 
is scarcely absorbed by animal tissues) in vivo BL molecular imaging is emerging as 
one of the leading imaging technologies in the areas of cancer biology, cell biology, 
gene therapy and stem cell research. Moreover, the advancements in molecular 
biology allowed to obtain organisms in which the expression of a BL protein is under 
the control of tissue-specific regulatory elements, allowing non-invasive imaging of 
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selected physiological or pathological processes. Furthermore, BL tomography 
enables 3D light source reconstruction to obtain, for example, tumor shape in small 
animals. However, many factors have to be considered when a BL molecular imaging 
experiment has to be settled up, for instance optical properties (scattering and 
absorption properties) and thickness of the tissue through which photons are 
travelling. Haemoglobin is the main chromophore within tissues absorbing light in the 
visible spectrum (400 to 760 nm) but, if the animal is pigmented, also melanin 
contributes to light absorption. Haemoglobin light absorption is significantly lower at 
wavelengths longer than 600 nm. Unfortunately, wild-type BL proteins usually emit in 
the blue-green spectral region and, therefore, much effort has been recently put to 
develop of red and near-infrared emitting BL proteins for in vivo imaging applications. 
Bacterial, firefly and Renilla luciferases are the most used BL reporter proteins in 
whole-body imaging. Bacterial luciferase is the only reporter protein that allows the 
construction of self-luminescent engineered organisms through the introduction in the 
cell of the whole lux gene cassette (luxCDABE), which contains the genes encoding 
both for luciferase and for the enzymes able to synthesize its BL substrate. 
Genetically engineered BL bacteria (Escherichia coli, Vibrio cholerae, Salmonella 
typhimurium) based on the luxCDABE system have been employed to localize 
tumors and metastasis in living animals. Such bacteria take advantage of the 
anaerobic microenvironment and the nutrient-rich growth conditions, being able to 
replicate in the necrotic central area of tumors.32 Besides tumor and metastasis 
localization, self-luminescent bacteria may have others promising applications, for 
example monitoring of bacteria-mediated gene product delivery systems for therapy 
of solid tumors. Firefly luciferase is by far the most employed BL protein in several 
bioanalytical applications. Mutant luciferases with different spectral properties have 
been developed by random and site-directed mutagenesis of P.  pyralis wild-type 
luciferase,
33
 and a single amino acidic residue (Ser284) appeared to be the most 
promising for developing mutants with altered emission properties.34 Besides 
emission color, also the thermostability of BL reporters is an important factor for in 
vivo imaging applications. Indeed, BL measurements performed in cell cultures and 
other in vitro assays are usually taken at room temperature, on the contrary in vivo 
imaging has to be performed at body temperature (37°C). A systematic study to 
investigate the thermostability of commercially available luciferases (FLuc+, CBGr68, 
CBRed, and hRLuc) was recently performed by Zhao et al, who reported a 34-nm 
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spectral red shift for the the firefly enzyme.35 The study showed that for all the 
investigated luciferases the activity increased with temperature, and the luciferases 
with the highest increments were CBGr68 (6.4-fold) and CBRed (7.8-fold). Spectral 
profiles are also affected by temperature and the most evident change was observed 
for firefly luciferase, whose emission maximum shifted from 578 nm at 25°C to 612 
nm at 37°C. A long-term continuous delivery system based on implanted micro-
osmotic pumps was also developed to overcome one of the main pitfalls of firefly 
luciferase, the need for the BL substrate D-luciferin.36 This system did not require 
repetitive injections of the BL substrate that, together with substrate 
pharmacokinetics, put constraints on intervals between image acquisition. 
 
BLI- based mouse models for drug discovery and development 
BLI has become a routine modality for use in cancer biology particularly suited for 
assessing tumor burden and metastatic spread. The most common use of BLI in 
cancer has been to assess mass and location of xenografted cells constitutively 
expressing luciferase, providing a robust strategy to monitor effectiveness of anti-
tumor drugs in vivo. Whole body BLI using firefly luciferase allows semi-quantitative 
measurements of tumor load and progression, metastasis and treatment response. 
Due to the sensitivity of BLI luciferase-expressing tumor cells can be transplanted to 
at any orthotopic site within a mouse or rat and subsequent tumor development, 
progression, and possible metastasis can be monitored in a rapid and time-sensitive 
manner. Also BLI has proven very useful for the early detection of micro-metastases 
and minimal residual disease states in animal37.38. Apart from preclinical studies on 
cancer BLI-based mouse models are routinely used by pharmaceutic companies 
since they provide information on where a drug or compound takes part in a specific 
regulatory pathway related to the disease. A growing number of luciferase expressing 
animal models are (commercially) available for drug metabolism and toxicology, 
disease areas like oncology/angiogenesis, metabolic -and neurodegenerative 
diseases and inflammation39-45. That is consequently to the development of the 
methodology for producing reporter animals by efficiently integrate luciferase gene in 
the mouse genome under the control of a specific promoter. Luciferase expressing 
mouse models can highlight the mechanism of many regulatory sequences. BLI can 
be used to monitor inflammation by driving luciferase with inflammation-specific 
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regulatory sequences. For instance, Carlsen et al. generated mice expressing 
luciferase under the control of the regulatory sequences of the NFκB gene, which in 
its turn is under the direct control of TNFα, a key cytokine produced during 
inflammation. Using NFκB-luciferase mice, Carlsen et al.46 monitored osteoarthritic 
inflammation induced by injection of bacterial lipopolysacharide, and quantified the 
therapeutic potential of dexamethasone treatment of the arthritic lesion. Moreover 
luciferase expressing animal models can be employed for studying drug availability 
and distribution47. 
 
Cell based assay in drug discovery and development 
Cell-based assays include a variety of assays that measure cell proliferation, toxicity, 
production of markers,motility, activation of specific signalling pathways and changes 
in morphology.Many of these assays rely on reporter gene technology. 
Due to signal amplification of cell-signalling cascades, reporter gene assays are very 
sensitive, and thus ideal forminiaturization; they have been widely applied in HTS 
formats48,49. Despite these advantages, such assays are based on signal-
transduction events that occur downstream of receptor activation and require gene 
expression. This causes long response times, which span from hours to days for the 
whole analysis time, and the possibility of interference from other intracellular 
pathways. For these reasons, alternative approaches relying on the monitoring of the 
first activation step, e.g., receptor dimerization, for example fluorescence and 
bioluminescence resonance energy transfer (FRET and BRET) and split 
complementation assays have also been proposed to satisfy the demands of HT 
drug discovery47-50. Recent improvements in optical imaging instrumentation and the 
wide choice of bioluminescent and fluorescent probes fuelled the implementation of 
cell-based assays for high-content screening (HCS). Because a very comprehensive 
overview has recently been published by Zanella et al. this review will not deal with 
HCS51. Cellular screening still presents a variety of challenges, and key aspects of 
improving this early phase of the drug-discovery process seem to be predictability, 
automation, miniaturization, cost-effectiveness, high-speed, and multiplexing.The 
state of the art, and challenges and future directions,will be discussed in this review, 
together with an up-to-date overview of recent ameliorations and trends in cell-based 
assays for drug discovery. 
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The implementation of reporter gene assays in thedrug-discovery process enables in 
vitro investigation of ADMET (absorption, distribution, metabolism, elimination, 
and toxicity) properties well in advance of animal studies. The main ADMET-related 
genes that have beentargeted are those encoding for drug metabolizing enzymes, for 
example the cytochrome P450 family(e.g., CYP3A4, CYP2B6, CYP2C9, and 
CYP2C19) anddrug transporters (e.g., MDR1, MRP2, MRP4, BSEP,BCRP, and 
NTCP) whose expression is regulated at thetranscriptional level by many of nuclear 
receptors (e.g., PXR, CAR, GR, and PPARα)52. The key advantages of reporter 
assays are highsensitivity, reliability, convenience, dynamic range, and adaptability to 
high throughput-screening. The major weakness encountered in their use is the high 
variability of cell response, mainly caused by sample-aspecificeffects on cell vitality. 
To improve robustness, an internalor external reference signal must be introduced in 
order to correct the analytical response and separate the specific signal from 
nonspecific interferences. This can be easily achieved by introduction of a second 
reporter gene which is constitutively expressed and whose activity thus parallels cell 
vitality. Commercial dual reporter assays with bioluminescence detection were 
introduced commercially to address this issue but, being based on the measurement 
of firefly and Renilla luciferase in the same sample, they require addition of a reagent 
to stop one reaction before adding the second substrate. This inevitably increases 
assay cost and time. More interestingly, use of new BL and fluorescent proteins with 
altered emission properties enabled simultaneous monitoring of more reporters in the 
same cell.The use of reporter proteins emitting at different wavelengths facilitates 
separation of the analytical and the control signals and expands the applicability of 
these reporters to multiplexed cell-based assays.The major pitfall of reporter gene 
assays is the possible disengagement between changes in enzyme activity and its 
corresponding mRNA levels. For example Lim et al. reported that antibiotic rifampicin 
and the natural furanocoumarin bergamottin (from grapefruit juice) both activate 
CYP3A4 gene transcription, but enzyme activity is increased by rifampicin and 
reduced by bergamottin, which is able to covalently inactivate the enzyme53.This 
disconnection can be hindered by reporter gene assays, which could thus be 
combined with other drug screeningassays to increase their predictability. 
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Multicolor luciferases for multiplexed analysis  
HTS reporter gene cell-based assays for lead identification are usually performed in 
serial or parallel mode and few multiplexed assays have been reported to date. 
Although the concept of multiplexed screening is well appreciated for image-based 
technologies, it is emerging as a more feasible option for plate-based, homogeneous 
assays, because implementation is simple, accessible, and cost effective. An efficient 
drug-discovery workflow needs the development of reliable information-rich assays. 
Recently, a cell-based transactivation high-throughput luciferase reporter assay has 
been developed to identify potential cytochrome P-450 3A4 (drug-metabolizing 
enzyme) inducers. This 384-well multiplexed homogeneous assay was developed 
and validated for simultaneous detection of PXR transactivation and HepG2 cell 
cytotoxicity by combining as fluorescence and bioluminescence readouts. When its 
analytical performance was compared with that obtained with the conventional 
singleplex PXR transactivation assay (with separate toxicity assay), using four well-
known PXR inducers, the reported EC50 values were not statistically different in 
either the singleplex or multiplex formats. The authors reported that switching from 
singleplex to multiplex reduced the overall number of cells by 29% and the 
consumable costs by 38%. Furthermore, use of cryopreserved cells with multiplexing 
and automation enabled elimination of a total of 92 processing steps (42% 
reduction)54. Some multiplexed reporter assays have been developed. For example, 
Nakajima et al. proposed a novel reporter assay system in which three luciferases 
that emit at different wavelengths (green, orange, and red) in the presence of the 
same substrate are used as reporter proteins. By using longpass filters and applying 
a signal processing algorithm, a cell-based monitoring system was developed for 
simultaneous evaluation of the expression of three different target genes within a cell, 
achieving a dynamic range of three orders of magnitude55. As an alternative, we 
proposed the combined use of secreted BL reporter proteins, for example Gaussia 
princeps luciferase, and intracellular proteins (the green-emitting P. pyralis luciferase 
and a red-emitting thermostable mutant of L. italica luciferase). We developed a 
multicolour cell-based assay for CYP7A1 and CYP27A1, the two main enzymes 
responsible for bile acid biosynthesis, and the secreted Gaussia luciferase was used 
as vitality control under the regulation of a constitutive promoter. The use of a 
secreted luciferase makes measurement of its activity straightforward, because its 
expression is measured simply by taking small aliquots of cell culture medium. 
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Besides, the combination of secreted and intracellular reporters in the same cell-
based assay has the advantage of complete absence of interference between the 
two luminescence signals, which are measured in separate wells of high-throughput 
microplate formats56. This concept could be easily applied in the drug screening 
workflow to improve consistency of cell-based assay results and reduce cost and 
time. 
 
Protein-protein interaction studies 
In the postgenome era, the analysis of protein expression, protein structure and 
protein-protein interaction is a much harder task since a global perspective is 
necessary to understand the complex network of interactions involving proteins, 
nucleic acids, co-factors and other unknown actors that participate to biochemical 
and pathological processes. Diverse technologies, ranging from protein affinity 
chromatography to library-based methods (e.g., phage display, two-hybrid system), 
clustered together under the term “proteomics”, have been developed to investigate 
protein expression and function in cells and organisms. Among these, elegant 
approaches relying on Bioluminescence Resonance Energy Transfer (BRET) and 
split reporter protein complementation and reconstitution strategies have been 
employed to investigate protein-protein interactions and explore biological 
pathways57. Bioluminescence Resonance Energy Transfer is a nonradiative 
resonance energy transfer occurring between a light-emitting luciferase donor and an 
acceptor fluorescent protein. When donor and acceptor are brought into close 
proximity (1-10 nm) to one another and are properly oriented each other, the former 
transfers its energy to the latter, which then emits. Since light emission from the 
donor takes place at a different wavelength than that from the acceptor, the energy 
transfer can be easily detected by measuring the ratio of the acceptor to the donor 
emission intensities. Such ratiometric output allows to compensate for well-to-well 
aspecific signal variations (e.g., due to different cell numbers in each well or signal 
decay across the plate). Because BRET strictly depends on the molecular proximity 
between donor and acceptor, it is suitable for monitoring the activation state of any 
protein (e.g., receptor or transcription factor) that undergoes association or 
conformational changes as a consequence of ligand binding. For example, to 
evaluate receptor dimerization the two subunits of the receptor are genetically tagged 
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either with the donor (e.g., Renilla or firefly luciferase) or the acceptor (e.g., a green 
fluorescent protein variant). When the activation of the receptor brings the donor and 
acceptor in a favourable position, BRET will occur. This phenomenon can be either 
observed in vitro using purified proteins or directly within the cells where the fusion 
proteins were produced58. Differently from Fluorescence Resonance Energy Transfer 
(FRET), BRET does not require a light source, therefore it is not affected by 
photobleaching, light scattering or autofluorescence, and direct excitation of the 
acceptor cannot take place. The intrinsic low background of BRET should allow 
either detection of weak interactions and performing experiments with low 
concentrated proteins. As of today, several combinations of BRET formats and 
reagents are available for proteomics applications, including receptor research and 
mapping of signal transduction pathways59. The first application of BRET 
methodology goes back to 1999 and regarded the study of the dimerization of 
cyanobacteria circadian clock proteins60. Bioluminescence Resonance Energy 
Transfer has been successfully applied in the study of receptor dimerization, like the 
insulin receptor61, and to the evaluation of the homo- and hetero-dimerization of 
opioid receptors in live cells62. Estrogen receptor homodimerization was studied with 
BRET and BRET2, a BRET variant in which the energy transfer occurs between 
Renilla luciferase and a green fluorescent protein mutant (GFP2)63,64. Extended 
BRET (eBRET) is also gaining popularity as a technique that allows the monitoring of 
protein-protein interactions in real time for many hours65. Split reporter-based BL 
imaging is a newly developed strategy for studying protein-protein and, more 
generally, intracellular interactions. It relies on the complementation-reconstitution 
concept, i.e., the spontaneous assembling (in some circumstances) of 
active/functional proteins from one or more polypeptide fragments. In the split 
reporter strategy, a BL protein is cleaved into N-terminal and C-terminal fragments 
and each fragment is linked to one of the target interacting proteins. When protein-
protein interaction brings the two fragments close each other, the complete 
functionality of the BL protein is recovered (Figure 11). This approach works either 
via protein segment complementation assays through a non-covalent assembly or via 
intein-mediated reconstitution assays based on covalent binding. A number of 
reporter proteins have been used for split protein strategies, for example firefly 
luciferase, Renilla luciferase, GFP, β-galactosidase66-69. 
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Figure 12: Schematic view of the split reporter-based complementation strategy. The N-
terminal and C-terminal halves of a reporter protein (e.g., luciferase) are genetically fused to 
a recognition element (receptor, ligand binding domain) through a short peptide linker. The 
interaction with the target analyte causes a conformational change that recovers the reporter 
protein activity through the protein complementation of split N- and C-terminal fragments. 
 
Recently a rapid screening assay based on a genetically encoded BL biosensor was 
developed to assess the androgenic effect of ligands by detecting the intramolecular 
association of the androgen receptor ligand binding domain (AR LBD)70. The authors 
demonstrated for the first time the possibility to use a single molecule-format BL 
probe to monitor cellular signalling steps. The AR LBD and the N-terminal domain of 
AR (AR NTD) where sandwiched between the dissected fragments of firefly 
luciferase. The association of AR LBD and AR NTD in the presence of androgens 
causes the complementation of the N- and C-terminal fragments of the luciferase, 
which partially recover its activity. Different chemicals known to possess agonist or 
antagonistic androgenic activity were assayed with this test, which was able to detect 
in a short time (20 minutes) as low as 10-5M dihydroxytestosterone (DHT). Recently, 
Kim and colleagues also validated a single-molecule-format complementation system 
of split click beetle luciferase (CBLuc) to investigate protein-protein interactions. The 
ligand binding domain of the androgen receptor was connected to a functional 
peptide sequence via a flexible linker. This fusion protein was sandwiched between 
the dissected N- and C-terminal fragments of CBLuc. In the presence of androgens, 
the association between AR LBD and a functional pepdide causes the 
complementation of N- and C-terminal fragments of CBLuc. After 20-min stimulation 
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of the MCF-7 cells carrying the fusion construct with 10-5M DHT luminescence 
intensities 29 times higher than a control were produced671 A combinatorial screening 
approach was used to identify novel firefly luciferase split sites with improved 
characteristics over the previously published ones72. A total of 115 different 
combinations were screened and the fragments were characterized with five different 
interacting proteins and an intramolecular folding strategy. A novel firefly luciferase 
split reporter showing increased sensitivity and complementation was identified, with 
potential application for the study of protein-protein and other interactions in cells and 
animal models. An intramolecular luciferase complementation probe for the detection 
of specific RNAs vas developed by constructing a peptide-inserted firefly luciferase 
containing short RNA-binding peptide sequences73. The same principle was applied 
by Kanno et al. to investigate the release of proteins from mitochondria toward 
cytosol74. For this purpose, a target mitochondrial protein was fused to a N-terminal 
fragment of Renilla luciferase and a N-terminal fragment of DnaE intein and 
expressed in the mitochondria of mammalian cells. If, for some reasons, the 
genetically modified target protein is released from the mitochondria, it interacts with 
a C-terminal fragment of DnaE interin fused to a C-terminal Renilla luciferase present 
in the cytosol, thus reconstituting an active Rluc. This method allowed high 
throughput screening of chemicals able to increase or inhibit the release of 
mitochondrial proteins in living cells and small animals.  
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In vivo bioluminescence imaging of murine xenograft cancer models 
with a red-shifted thermostable luciferase 
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Abstract  
Purpose. Conventional in vivo bioluminescence imaging using wild-type green-emitting 
luciferase is limited by absorption and scattering of the bioluminescent signal through 
tissues. Imaging methods using a red-shifted thermostable luciferase from P.pyralis were 
optimized to improve the sensitivity and image resolution. In vivo bioluminescence imaging 
performance of these red- and green-emitting luciferases were compared in two different 
xenograft mouse models for cancer.  
Methods. HepG2 (human hepatoblastoma cell line) and Thp1 (human acute monocytic 
leukemia cell line) cells were genetically engineered using retroviral vector technology to 
stably express the red-shifted or the wild-type green luciferase. A xenograft model of liver 
cancer was established by subcutaneous injection of the HepG2 engineered cells in the flank 
regions of mice, and a leukemia model was generated by intravenous injection of the 
engineered Thp1 cells. The cancer progression was monitored with an ultrasensitive charge-
coupled device (CCD) camera. The relative intensities of the green- and red-emitting 
luciferases were measured and the resulting spatial resolutions of the images were 
compared. Imaging was performed with both intact and scarified live animals to quantify the 
absorption effects of the skin and deep tissue.  
Results. The red-emitting luciferase was found to emit a bioluminescence signal with 
improved transmission properties compared to the green-emitting luciferase. By imaging the 
HepG2 models, which contained tumours just beneath the skin, before and after scarification, 
the percentage of light absorbed by the skin was calculated. The green bioluminescent signal 
was 75%±8 absorbed by the skin, whereas the red signal was only 20%±6 absorbed. The 
Thp1 model, which contains cancer cells within the bones, was likewise imaged before and 
after scarification to calculate the percentage of light absorbed by all tissue under the skin. 
This tissue was responsible for 90%±5 absorption of the green signal, but only 65%±6 
absorption of the red signal.  
Conclusion. Two different bioluminescent mouse cancer models demonstrate the utility of a 
new red-shifted thermostable luciferase, Ppy RE-TS, that improved the in vivo imaging 
performance when compared with wild-type P. Pyralis luciferase. While wild-type luciferase is 
currently a popular reporter for in vivo imaging methods, this study demonstrates the 
potential of red-emitting firefly luciferase mutants to enhance bioluminescence imaging 
experiments. 
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Introduction 
Amongst the recent molecular imaging approaches, including Positron Emission 
Tomography (PET), Single Photon Emission Computed Tomography (SPECT) and 
Magnetic Resonance Imaging (MRI), Bioluminescence Imaging (BLI) with luciferase 
reporters is continuously gaining popularity and is largely applied in preclinical cancer 
research. BLI is often preferred because it provides a simple, sensitive, robust 
imaging modality with relatively cost-effective instrumentation. BLI and Fluorescence 
Imaging (FLI) systems are based on the use of bioluminescent reporter genes such 
as luciferases or fluorescent proteins expressed in cells (e.g., cancer cells, stem 
cells, bacteria) that are inoculated into small experimental animals and imaged in 
vivo with the use of ultrasensitive charge-coupled device (CCD) cameras, able to 
detect light emission even from deep tissues [1,2,3].Throughout the last decade, BLI 
has been used in xenograft animal cancer models to investigate the factors involved 
in malignant transformation, invasion and metastasis, and to examine responses to 
cancer therapy [4]. Such animal models are quite accessible to researchers, because 
they are easy to make and simple to use. In vivo BLI with these models allows for 
direct or indirect physiological imaging of specific cellular and molecular events. To 
initiate the luciferase reaction, luciferin substrate must be intravenously (i.v.) infused 
or intraperitoneally (i.p.) administered to the animal in sufficient concentration to 
saturate the reporter enzyme at the anatomical region of interest. Almost all 
luciferases require the administration of the substrate with the exception of bacterial 
luciferase, since the lux operon cassette codes not only for the luciferase but also for 
enzymes to produce the substrate. Unlike fluorescent reporter proteins, which require 
an excitation source, luciferase reporters generate a highly detectable BL signal with 
virtually no background noise, resulting in impressive imaging sensitivity. Luciferase 
from the North American firefly Photinus Pyralis provides a particularly strong signal, 
due to the high quantum yield (~0.41) of the luciferase/luciferin reaction [5]. The 
choice of luciferase in a BLI system is a crucial means by which to ameliorate and 
optimize the imaging technique. Though P. Pyralis luciferase is the most common 
choice, luciferase from the sea pansy Renilla reniformis, the green- and red-emitting 
luciferases from the click beetle Pyrophorus plagiophalamus and luciferase from the 
copepod Gaussia princeps have also been investigated  [6,7]. Most of these 
enzymes emit in the blue/green region of the UV/vis spectrum, where light is strongly 
absorbed and scattered by tissues. Consequently, the imaging performance suffers 
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from poor sensitivity and spatial resolution. While green light is strongly absorbed by 
haemoglobin, melanin and other pigmented macromolecules, light greater than 600 
nm in wavelength is less strongly absorbed [8], and can travel through living tissue 
over a much greater distance (1/e absorption length in tissues of  2cm) [9]. Despite 
the advanced transmission properties of red-emitting luciferases, the red click beetle 
luciferase recently proposed for molecular imaging was demonstrated to be non-
suitable for in vivo imaging due to its poor thermostability [10]. Recently, a 
thermostable red-shifted mutant of luciferase from P. pyralis  was created by random 
and rational mutagenesis [11].This luciferase, named Ppy RE-TS, has an emission 
maximum of 612 nm at pH 7.0, a narrow emission bandwidth and excellent 
thermostability (the half-life at 37°C is 8.8 hrs, versus 0.26 hrs for wild-type 
luciferase). We report here the in vivo optical and luminescence properties of PpyRE-
TS, and we present evidence for its potential to enhance BLI systems if used in place 
of, or in addition to, Photinus pyralis luciferase (WT). These two luciferase reporters 
were assessed for their applicability in visualizing cancer growth and for 2D 
localization imaging in two murine cancer models.A liver cancer mouse model, 
produced for solid tumour monitoring, was developed using HepG2 cells (human 
hepatoblastoma cell line) stably expressing WT or Ppy RE-TS. The cells were 
inoculated subcutaneously into the flanks and the upper backs of immunodeficient 
mice. A leukemia mouse model, produced for monitoring solid metastasizing 
tumours, was developed using Thp1cells (human acute monocytic leukemia cell line) 
stably expressing WT or Ppy RE-TS. These cells were intravenously injected into 
immunodeficient mice.The two luciferase reporters were used to visualize the cancer 
progression and distribution in both animal models over five weeks, so as to compare 
green- and red-emitting luciferase performance and to determine the best 
experimental conditions for in vivo BL imaging. 
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Material and Methods 
Construction and generation of lentiviral particles encoding Ppy RE-TS or WT 
luciferase from P. pyralis 
The previously reported pGex plasmid to express Ppy RE-TS (7) was amplified by 
PCR using the 3‟ primer-atcctcgagatggaagacgccaaAaacat (XhoI) and the 5‟ primer-
gctagatctttactttccgcccTTcTTggc (Bglii) and inserted into the pMCSVneo plasmid 
(Clontech, Palo Alto,CA, USA) to create pMCSVPpyred-ts-neo. The XhoI and BglII 
restriction sites for used for cloning are shown in italics. For the construction of viral 
particles encoding the WT luciferase gene, the pMMPLuc-neo vector (kindly provided 
by Prof. A Kung) was used. Retroviral vector particles encoding WT or Ppy RE-TS 
were produced in the 293T packaging cell line by transient transfection with jetPEI 
transfection reagent (Polyplus Transfection, Illkirch, France). The viral stock was 
collected at 48h and 72h post transfection and filtered with a low-protein-binding 0.45 
µM filter. The 293T cells were imaged with the low-light imager system LB981 
(Berthold technologies, Bad Wildbad, Germany) after addition of D-luciferin (Beetle 
Luciferin Potassium Salt, Promega, Madison, WI, USA) at 72h to control the 
efficiency of transfection.  
Generation of luciferase-positive hepatoblastoma and acute monocytic 
leukemia cell lines 
Human hepatoblastoma (Hepg2) cells were cultured in DMEM (Sigma, St. Louis, 
MO,USA) with 10% fetal bovine serum, 2mM L- glutamine, 0.1mM non-essential 
amino acids, and 1% vitamin solution (Sigma, St. Louis, MO,USA). Human acute 
monocytic leukemia (Thp1) cells were cultured in RPMI1640 medium with 10% fetal 
bovine serum. All cultures were incubated at 37°C with 5% CO2. HepG2 cell lines at 
60-70% confluency were transduced by addition of 2 ml viral stock. Thp1 cells were 
transduced by spinoculation [12]. To facilitate vector penetration of the cells, 8 g/ml 
of Polybrene (hexadimethrine bromide, Sigma, St. Louis, MO, USA) was added to 
virus-containing media. Cells were incubated overnight, then washed twice with PBS 
(phosphate-buffered saline: NaCl 137mM, KCl 2.7mM, NaH2PO4 1.4mM, Na2HPO4 
4.3mM, pH 7.2). Cultures were grown for another 24h in the original media described 
above. Cell clones stably expressing luciferase were selected with 1 g/ml G418 for 
14 days. Positive HepG2 and Thp1 cell clones were termed HepG2-Luc or Thp1-Luc 
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when expressing WT luciferase, and HepG2-Ppyred or Thp1-Ppyred when 
expressing Ppy RE-TS. 
In vitro bioluminescence measurements  
Cell clones showing the highest BL emission were selected by the following intact-
cell luciferase assay: 100 l of cell suspension at a density of 106/ml was transferred 
to a white 96-well cell culture microplate and luminescence signals collected by 
adding 100 l of the Luciferase Assay System substrate (Promega, Madison, WI, 
USA) using a spectral scanning multimodal plate reader (Varioskan Flash, Thermo 
Scientific, Whaltham, MA, USA). The selected luciferase-expressing clones were 
assayed for bioluminescence emission spectra, as well. A 100 l sample of cell 
suspension (106/ml) was transferred to a 96 well microplate. After 100 l of 
Luciferase Assay System substrate was added, emission spectra were collected from 
500-670 nm by measuring the light output at 2 nm intervals for 1 s. Luminescence 
measurements were performed at room temperature (25°C).To prove that photon 
emission and viable cell count were linearly related, HepG2-Luc, HepG2-Ppyred, 
Thp1-Luc, and Thp1-Ppyred cells were each plated in triplicate in a series ranging 
from 1x106 to 4x103 cells diluted in PBS. After receiving 100 l of Luciferase Assay 
System substrate, the cells were incubated for 5 minutes and then imaged for 1 
minute with the same region of interest (ROI) used to measure luminescent signals of 
cells in each well.  
Mouse cancer models 
Animal experiments were approved by the Bioethics Committee of Bologna 
University in compliance with international guidelines. The liver cancer model was 
developed using five 14 week-old NOD/SCID mice purchased from Charles River 
laboratories (Wilmington, MA, USA). Subcutaneous xenografts were established by 
injection of 5x105 HepG2-Luc and HepG2-Ppyred cells in the upper backs of the 
mice. For experiments monitoring both red and green bioluminescence in a single 
mouse, each mouse was injected also with 106 HepG2-Luc cells in the right flank and 
2.4x106 HepG2-Ppyred cells in the left flank. The leukemia animal model was 
developed using ten 6 to 10 week-old NOD/SCID mice. Each mouse was 
intravenously injected with 5 x106 Thp1-Luc or Thp1-Ppyred cells and the cancer 
progression was monitored every 7 days for a total of 5 weeks.  
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In vivo bioluminescence imaging 
Mice anesthetized with 0.3 mg/kg body weight Zoletil 100 (Virbac s.r.l., Carros 
Cedex, France) were i.p. injected with 150 mg/kg D-luciferin (Synchem OHG, 
Felsberg, Germany) dissolved in PBS, and were imaged with the low-light imager 
system LB981. To investigate the kinetics of the in vivo reactions, mice inoculated 14 
days prior with HepG2-Luc or Thp1-Luc cells were imaged for 20 minutes with 
sequential one-minute exposures. Mice were imaged for 20 minutes with sequential 
one-minute exposures during imaging sessions conducted immediately after i.p. 
injection of D-luciferin  The collected images were used to generate kinetics plots for 
both luciferases, which were used to determine the optimal temporal windows for 
subsequent experiments (Fig. 3).Mice inoculated with HepG2-Luc and HepG2-
Ppyred cells were placed in prone positions inside the instrument and imaged for 
three minutes, beginning 8 minutes after the luciferin injection. For each acquisition, 
the bioluminescent signal from the ROI was depicted as a pseudocolor image 
superimposed on a greyscale photographic image. Images of mice inoculated with 
Thp1-Luc and Thp1-Ppyred cells were collected both in prone and supine position for 
3 minutes, beginning 8 minutes after the luciferin injection, and the luminescent 
signal was calculated as the sum of the two acquisitions. Data are reported as the 
photon flux (ph/s) from a total body ROI of 5000mm2. At the end of the study, 3 mice 
of the HepG2 xenograft model, 3 mice of Thp1-Luc and 3 mice of Thp1-PpyRed 
xenograft model underwent scarification during the imaging sessions. Briefly, animals 
were anesthetized and injected with D-luciferin as described before, then mice were 
positioned inside the instrument and imaged for 1 min before and after scarification. 
The surgery was performed as follows: an incision was made on the back of the mice 
and the skin layer was removed, the same procedure was used for removing skin 
layer from the leg of the mice.  
Quantitative analysis 
The Winlight software version 2.9 of the low-light imager system LB981 was used to 
analyze and graphically present the BL data. Linear regression analysis was used to 
determine correlation between bioluminescence signal intensity and number of cells. 
For the HepG2 xenograft mouse model, bioluminescence intensity and tumour 
progression are reported as mean ± standard error of the mean (SEM) of the the ROI 
photon flux (ph/s) after background subtraction. For Thp1 xenograft mouse model, 
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bioluminescence intensity and tumour progression are reported as the mean ± SEM 
of the summed prone and supine signals (with subtraction of background for every 
acquisition) for every mouse. A total of 5 animals were used for HepG2 xenograft 
mouse model and 10 for Thp1 xenograft mouse model. Statistical analysis was 
performed using Graph Pad Prism v.5 for Windows, p<0.05 was considered 
significant. 
Results  
In vitro analysis of luciferases in transfected cell lines 
Prior to developing the xenograft models, the Ppy RE-TS and WT luciferases were 
expressed and characterized in cell cultures for comparitive analysis. Expression of 
luciferase in Thp1-Luc and HepG2-Luc cell clones transduced with pMMPLuc-neo 
was monitored in whole cells as described in Materials and methods. Cell viability 
was monitored with a trypan blue exclusion assay. The bioluminescence emission 
spectra of intact cell clones are shown in Figure 1. HepG2-Luc cells produced an 
average signal of 2000 relative light units (RLU), at an emission maximum of 562 nm, 
whereas HepG2-Ppyred produced an average signal 1000 RLU at an emission 
maximum of 612 nm. At the same emission maxima, Thp1-Luc cells emitted 2x104  
RLU and Thp1-Ppyred cells emitted 600 RLU. The lower BL emission intensity of Ppy 
RE-TS in both cell lines can be attributed to the lower specific activity, which was 
approximately 15% that of wild-type luciferase when measured in pure proteins by 
Branchini et. al. [11]. Nevertheless, this relatively low specific activity is balanced by 
the extremely high thermostability of the enzyme in both cell lines. This confirms data 
(37°C half-life=8.8 h)  previously reported by Branchini et al., which were obtained 
using the purified enzyme [11]. 
Correlation between cell number and photon emission in vitro. Dilution series of 
selected clones stably expressing WT luciferase or the Ppy RE-TS mutant were 
imaged in triplicate as described in Materials and methods. The linear relationship 
between the viable cell count, determined by a trypan blue exclusion assay, and BL 
signals for each cell clone (HepG2-Luc, Thp1-Luc, HepG2-Ppyred and Thp1-Ppyred) 
is reported in Figure 2. The correlation coefficient was greater than 0.98 for all cell 
clones. Using the same quantity of cells, the highest BL intensity was obtained with 
the Thp1-Luc, followed by HepG2-Luc, HepG2-Ppyred and Thp1-Ppyred. 
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Figure 1. Emission spectra of green-emitting Thp1-Luc and HepG2-Luc clones (straight line, left Y 
axis) and red-emitting Thp1-Ppyred, and HepG2-Ppyred clones (dot line, right Y axis). Spectra were 
obtained by addition of Luciferase System Assay substrate to 1x10
5
 intact cells resuspended in PBS in 
96-well microtiter plate. Each experiment was performed in triplicate and repeated three times.  
 
Figure 2.A. Pseudocolor image of flux values in photons per second for serial dilutions of HepG2-Luc 
and Ppyred ranging from 1.2x10
4
 to1x10
6
 cells 2.B. Correlation between the number of cells and 
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luminescent signals for each cell clone: HepG2-Luc, Thp1-Luc, HepG2-Ppyred, Thp1-Ppyred. (R
2
> 
0.98, P<0.001, n=3) 
BLI of the hepatoblastoma (HepG2) xenograft murine model  
In vivo comparison between green- and red-emitting luciferases.  The difference 
between red and green light transmission through tissues was evaluated first by 
inoculating individual mice with two cell cultures, 106 of HepG2-Luc cells in the right 
flank and 2.4x106 of HepG2-Ppyred cells in the left flank. These cell counts were 
chosen based on the previously described in vitro experiments, which indicated that 
106 of HepG2-Luc cells and 2.4x106 of HepG2-Ppyred cells bioluminesce with a 
similar intensity and showed a mean signal of 9,2±0,5 x 106 ph/s/mm2 when detected 
with the imager. Using one animal with two inoculations made it possible to normalize 
the initial BL intensity of inoculated cells and thus compare the green and red light 
transmission through the skin and fur. The whole animal BL emission from the 
HepG2-Ppyred cells was much higher than that obtained from HepG2-Luc, with a 
mean recovery of the red photons(2,3±0,3 x105ph/s/mm2) three times higher than 
that of the green photons (7,8±0,3 x104ph/s/mm2). These results are consistent with 
previous experiments, wherein mice were injected with nude plasmids encoding WT 
luciferase and a red-emitting luciferase (S284T)[13]. 
Serial BLI of tumour burden and substrate-mediated light emission kinetics. The 
tumour progression and the performance of Ppy RE-TS in comparison with WT 
luciferase were studied by subcutaneous injections in the flank regions and the upper 
back of each mouse. Rather than normalizing the cell quantities according to in vitro 
results, as in the protocol above, HepG2-Luc cells (right flank) and HepG2-Ppyred 
cells (left flank) were injected in similar quantities (5x105). The imaging conditions 
were optimized by adjusting the temporal window of measurement according to the 
emission kinetics. The kinetic experiments, performed as described in Materials and 
methods, indicated that the maximum signal intensity is reached 8-12 minutes 
following the i.p. injection of D-luciferin, followed by a slow decrease of the 
luminescent signal(Fig. 3). Accordingly, BL images were collected 8-12 min after the 
i.p injection, which was performed every seven days for five weeks to track cancer 
progression. By day 7 the BL signal was clearly visible for both the WT and Ppy RE-
TS luciferases (Fig. 4), confirming the suitability of the red-emitting enzyme for 
monitoring early tumour onset and progression. Furthermore, after 20 days the red-
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emitting luciferase exhibited an 5-fold greater BL intensity with respect to the WT 
luciferase. 
Scarification studies to compare red and green signal absorption in vivo. To quantify 
the percentage of light absorbed by the skin, HepG2 mice were imaged before and 
after scarification. We calculated that 75±8% of the light generated by WT luciferase 
was absorbed by skin while only 20±6% of the light generated by red-shifted 
luciferase was absorbed. data reported the mean percentage of six different red and 
green tumor.  This result is in agreement with previous evidence that light emitted 
from red-shifted luciferase passes through tissues three times more efficiently than 
does green light [13]. Additionally, the tumour mass evaluation after scarifying the 
animals revealed differences in tumour dimensions: the red-emitting tumour 
produced by 1x105 HepG2-Ppyred cells was two times bigger than the green-emitting 
tumour produced by 1x105 HepG2-Luc cells. The higher replication rate of the 
selected HepG2-Ppyred clone resulted in superior tumour detectability both at 
tumour onset and during progression. For example, at day 21 the red BL was 6x107 
photon/sec whereas the green BL was 8x106 photon/sec. 
 
 
Figure 3. Kinetics measurements of in vivo emissions after intraperitoneal injection of D-luciferin 150 
mg/Kg performed by collecting images with 1 minute of exposure for 20 minutes for both xenograft 
cancer models. 
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Figure 4. Serial BL imaging of mice inoculated with HepG2-Luc (on the right side) and HepG2-Ppyred 
cells (on the left side). Subcutaneous tumor on the upper back are generated inoculating different 
amount of cells but with the same initial emission while tumour on the lower flanks are generated 
inoculating the same amount of cells. Pseudocolor images have been generated on a common scale. 
 
BLI of the Acute Myeloid Leukemia (Thp1) xenograft murine model 
In vivo comparison between green- and red- emitting xenograft models. Unlike 
HepG2 cells, Thp1 leukemia cells metastasize to unpredictable locations, [14] so it 
was not possible to study both red- and green-emitting tumours simultaneously in a 
single mouse.  Instead, mice were intravenously injected in the tail vein with 5x106 
Thp1-Luc or 5x106 Thp1-Ppyred cells. After 14 days, solid tumours were detected in 
both groups of mice, and kinetics experiments were performed to optimize the 
imaging method for subsequent experiments. Following intraperitoneal injection of D-
luciferin, the luciferase emission kinetic plot for Thp1-Luc reaches a plateau within 10 
min and slowly decreases after the 15 minute point (Fig. 3). Therefore, the selected 
temporal window was from 8 to 15 min, during which both prone and supine images 
were acquired (Fig.5).  The optimized D- luciferin administered dose was 150 mg/kg 
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as previously reported [15,16]. Mice were imaged during this 8-15 minute window 
every seven days for five weeks. Tumour growth was tracked by measuring the 
increase in bioluminescence signal intensity over time (Figure 6). Primary sites of cell 
proliferation, determined by immunohistochemistry (data not shown), were bone 
marrow, femur or backbone while secondary sites were the humerus, spinal cord 
and, in one individual, the head. 
Scarification studies to compare red and green signal absorption in vivo. To evaluate 
the differences between green and red light emission from bone after skin removal, 
imaging studies were conducted using three mice inoculated with Thp1-Luc cells and 
three inoculated with Thp1-Ppyred. Comparing the data from the skinless and intact 
mice, we calculated that 90%±5 of the green light and 65%±6 of the red light was 
absorbed by deep tissues when emitted from the bones. Data relative to calculations 
are reported in Table1. 
 
Figure 5. Serial BL imaging of mice inoculated with Thp1-Luc (Upper images) or Thp1 -Ppyred cells 
(lower images).  
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Figure 6. BL intensity signals revealing tumor progression in mice inoculated with Thp1-Luc ( 
triangle)or Thp1 -Ppyred cells (square). Signals were consistent after 14 days, and showed a rapid 
increase after metastasis formation. 
 
 
Figure 7. Pseudocolor images on a common scale  of HepG2-Ppyred red tumours (on the left) and 
HepG2-Luc green tumours (on the right) before and after scarification.  
Discussion 
Seeking an improved probe for BL imaging, we compared the in vivo optical 
properties of Ppy RE-TS and WT luciferase in two xenograph murine models [17]. 
Two cell lines, HepG2 and Thp1, were transduced with retroviral particles containing 
the WT luciferase gene from Photinus Pyralis or the red-emitting mutant gene Ppy 
RE-TS. The long-term stability of luciferase expression in a medium without selective 
agents was confirmed by monitoring light emission over a 2-week period. For each 
clone (HepG2-Luc, Thp1-Luc, HepG2-Ppyred and Thp1-Ppyred) luminescence 
intensity and bioluminescence spectra were measured from intact cell suspensions to 
confirm the behaviour of WT and red mutant in whole cells as they are inside the 
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animals. The luminescence intensity of HepG2-Ppyred cells was 2-fold lower than 
the HepG2-Luc signal, and the Thp1-Ppyred signal was 33-fold lower than the Thp1-
Luc signal (Fig. 1). These results in part reflect  the relatively low specific activity of 
Ppy RE-TS (15% of WT) observed in pure protein assays [11].On the other hand 
different expressing cell clones are due to the use of different plasmid and method 
used to transduce cells and to G418 selection that bring to a random and possible 
multiple integration of the constructs inside cell genome. Yet our results also 
confirmed that cells expressing Ppy RE-TS have a red-shifted bioluminescence 
max max = 562 
nm) (Fig. 1). Because red light has a lower attenuation rate in living tissue compared 
to green light, we anticipated that the lower luminescence intensity of HepG2-Ppyred 
and Thp1-Ppyred in cell assays would be counterbalanced by the red-shifted spectra 
of these cells in vivo. We also predicted that the superior thermostability of Ppy RE-
TS at 37C could confer some advantage in the in vivo environment, though we did 
not perform controlled experiments to isolate this variable. In preparation for in vivo 
experiments, it was necessary to demonstrate a positive correlation between light 
emission and viable cell count. An impressive linear correlation was obtained for all 
four clones, validating the use of stable light emission from our models as a 
quantitative marker of tumour burden (Fig. 2) [18]. Also, we observed a ratio of 2.4 
between HepG2-Luc and HepG2-Ppyred emission signals; this value was employed 
for normalization of light emissions in vivo. In vivo BLI experiments were performed 
with xenograft murine models for hepatoblastoma (HepG2 cell line) and acute 
myeloid leukemia (Thp1 cell line). While BLI would be most sensitive in nude mice, 
we chose white-coated NOD/SCID mice, since they more accurately represent typical 
xenograft murine models used in other laboratories. We optimized the in vivo imaging 
technique by performing preliminary kinetics studies (Fig. 3). Because the HepG2-
Luc kinetics plot showed an intense and stable signal from 8 min to 15 min, a result 
consistent with published values [15,16], images were obtained in this temporal 
window after the injection of D-luciferin. The optical properties of the two luciferases 
in the hepatoblastoma model were evaluated by inoculation of HepG2-Luc and 
HepG2-Ppyred cells in the right and left flanks of each mouse, respectively (Fig. 4). 
By adjusting the injected quantities of red- and green-emitting cells to normalize the 
two bioluminescence signals, protein specific activity was eliminated as a variable. 
Immediately following inoculation, the bioluminescence signal produced by the red-
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emitting cells was almost 60% higher than the light signal produced by the green-
emitting cells, an advantage which can be attributed to the red-shifted spectrum 
alone. After five weeks the tumour masses were consistent, and 3 mice were imaged 
before and after scarification to determine the percentage of light absorbed by the 
skin. We calculated that 75%±8 of the light generated by WT luciferase was 
absorbed through skin while only 20%±6 of the light generated by red-shifted 
luciferase was absorbed. This result is in agreement with previous evidence that light 
emitted from red-shifted luciferase passes through tissues three times more 
efficiently than green light [13]. As expected, BL signal intensity depended not only 
on signal transmission, but also on the rate of tumour growth, which varied according 
to the replication rates of the cell clones selected. The HepG2-Ppyred cells, which 
showed the highest in vitro replication rate among the four selected clones, produced 
the brightest BL signal after 20 days. While the higher replication rate of the red-
emitting clones was coincidental it illuminates another variable that can be optimized 
for BL imaging. Xenograft models for acute myeloid leukemia were developed to 
show the suitability of Ppy RE-TS for probing not only solid tumours, but also 
metastasizing tumours. NOD/SCID mice were inoculated with Thp1 cells by tail vein 
injection, and tumour progression was monitored by weekly imaging sessions for five 
weeks. After 14 days, solid tumours were detected in both groups of mice, with the 
BL signal localized in the bones (Figure 5). The period until tumour detection 
depends on the speed of critical cell mass formation and the strength of the in vivo 
BL signal. Images collected from Thp1-Ppyred model provided the first experimental 
evidence that the red emitting luciferase can be successfully used to develop 
xenograft cancer models since the tumor behaviour is analogous to the green one 
obtained with the conventional wild type luciferase. Moreover tissue absorption of the 
green and red light emissions was compared by performing BL imaging with and 
without skin removal, as described in Materials and Methods section. Three Thp1-
Luc and Thp1-Ppyred mice were imaged before and after scarification to calculate 
the signal lost due to tissue attenuation alone.  The tissues absorbed 90±5% of the 
green light generated from the cancerous bones, but only 65±6% of the red light was 
absorbed. These calculations are further evidence that Ppy RE-TS provides a 
superior imaging performance to WT luciferase not only when used immediately 
beneath the skin, but also when used for deep tissue experiments. Thanks to its 
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reduced scattering the Ppy RE-TS appears to be a viable alternative to WT luciferase 
for molecular imaging techniques.  
Conclusion 
After comparing the in vivo imaging performance of wild-type luciferase from P. 
Pyralis with the red-emitting mutant Ppy RE-TS from the same species, we found that 
Ppy RE-TS produced a more intense and less scattered bioluminescence signal [19]. 
This enhanced performance was observed in spite of the lower specific activity of 
Ppy RE-TS relative to the WT luciferase, and therefore attests to the advantage of 
using a red reporter instead of or in addition to a green reporter for in vivo imaging. 
An additional advantage that may have contributed to the success of Ppy RE-TS is 
its high thermostability at 37C, though the effects of this variable were not isolated in 
this study. These results strongly suggest that although early xenograft murine 
models were developed using wild-type P. Pyralis luciferase,[20] and most of the 
published work has used this reporter, red-emitting luciferases could greatly improve 
BLI systems. The limitations that afflict BL imaging, mainly optical absorption and 
scattering by tissue, could be overcome by using red-emitting reporters for greater 
sensitivity. Improved light-collection methods may also advance emerging 
technologies such as BLI tomography and 3D in vivo imaging, which has not yet 
been performed with a red-emitting luciferase [21-23].Because the red- and green-
emitting luciferases reported here emit light in well-separated spectral regions, it is 
also possible to use both reporters simultaneously, employing transmission filters to 
separate the two signals. As demonstrated in these studies, using two luciferases is 
a convenient method for visualizing two independent physiological events in one 
animal, since only a single substrate required for injection. To further tailor 
luciferases for in vivo applications, random and site-directed mutagenesis may be 
performed to increase enzyme activity or to codon-optimize the genes for greater 
expression in mammalian cells. Using enhanced luciferase mutants for 
bioluminescence in vivo imaging will render it an even more powerful tool for studying 
tumour growth, metastasis and, more generally, for conducting preclinical 
investigations in animal models. 
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Chapter 3 
 
A new gastric-emptying mouse model based on in vivo non-invasive 
bioluminescence imaging 
Roda A, Mezzanotte L, Aldini R, Michelini E, Cevenini L. 
Neurogastroenterol Motil. 2010 Oct;22(10):1117-e288. 
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Abstract 
Background: Different techniques were used to assess gastric emptying (GE) in small 
animals; most of them require sophisticated equipment, animal sacrifice and are expensive. 
In the present investigation a simple, non invasive method based on bioluminescence 
imaging (BLI) is reported to study GE, using light-emitting E. coli cells as a marker of the 
gastric content.  
Methods: A new thermostable red-emitting luciferase was chosen as reporter gene to 
transform E. coli cells. Bioluminescent (BL) bacteria were administered to fasting mice, after 
a solid meal, and in response to different doses of metoclopramide and hyoscine 
butylbromide. BLI allowed to evaluate the real time 2D spatial and temporal distribution of 
bacteria along the gastrointestinal tract in animals and to calculate GE rate in basal 
conditions and following pharmacological stimulation. 
Key Results: The administered BL bacteria were easily imaged and localized in the stomach 
and subsequently followed in the duodenum and upper intestine allowing to accurately 
calculate GE. GE after the test meal was significantly slower (T1/2 16±3 min) than that 
obtained in fasting conditions (T1/2 2±1 min); administration of hyoscine butylbromide (1 
mg/Kg b.w.) significantly (p<0.05) increased T1/2 that was delayed up to 25±4 min; 
metoclopramide (1 mg/Kg b.w.) significantly (p<0.05) accelerated T1/2, that was achieved 
within 8±2 min. 
Conclusion and Inferences: The reported model is simple, inexpensive, reliable, sensitive 
and accurate; it can detect both acceleration and slowdown of GE. The model is useful in the 
investigation of new drug-induced alterations of gastric motility allowing to reduce the number 
of experimental animals. 
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Introduction 
The mechanisms regulating gastric emptying (GE) are very complex. Abnormal GE 
often results from impaired myogenic, intrinsic or extrinsic neural, hormonal or central 
control mechanisms [1-4]. Pathophysiological studies of gastrointestinal motility and 
the development of drugs acting on the gastric organ motor function require the 
availability of suitable in vivo animal models. The ideal animal model for drug 
screening should be minimally invasive, reproducible and follow the 3R‟s roles: 
replacement, reduction, refinement using as few animals and as responsibly as 
possible.Mice have been recently re-examined as small animals suitable for 
gastrointestinal motility studies [5-9] and the more recent availability of transgenic 
mice largely stimulates their choice [10,11].Different techniques have been used to 
assess GE in small animals [12-20] and most of them need animal sacrifice to 
analyze, in the gastric and duodenum content, radioactive beads [18] or marker dyes 
such as phenol red with spectroscopic techniques [16]. A less invasive technique is 
based on 13CO2 breath analysis in mice after administration of 
13C-labelled substrates 
such as 1-13C-octanoic acid and 13C-acetate as markers of gastric emptying [19,21-
23]. This method is minimally invasive but requires a special cage for breath 
collection over time and isotope ratio mass spectrometry.Imaging techniques are 
potentially more powerful and scintigraphy and magnetic resonance imaging have 
been proposed [20, 24-27] in intact animals as well as X-Ray imaging [9]. The 
application of these technologies for routine screening of drugs in laboratory animals 
is impractical due to expense and/or slow throughput. An ideal marker for GE 
evaluation should have peculiar features: firstly it must not interfere with GE rate, it 
must not adhere to stomach wall or be absorbed by gastrointestinal tract, it must be 
stable in gastric juice and it should have good imaging properties. We envisaged the 
possibility to use bioluminescent (BL) cells that, once orally administered, follow the 
fate of the gastric content and provide a real time image of the kinetics of the gastric 
content release into the duodenum and upper intestine. We employed for the first 
time functional in vivo molecular bioluminescence imaging (MBLI) to calculate the GE 
half-time in control mice and to evaluate the effect of drugs. The light emitted by the 
cells in part penetrates through tissues and is imaged with an ultrasensitive charge 
coupled device (CCD) camera. The methodology to prepare bioluminescent cells is 
well established and instrumentation for MBLI is relatively simple and economic when 
compared with MRI, PET or scintigraphy. The BLI technology has been recently 
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successfully applied for the development of xenograft cancer animal models [28,29] 
providing similar performance to microPET [30]. Here we report the development and 
validation of a new non invasive mouse model for GE rate evaluation using a 
bioluminescent non pathogen strain of E. coli, expressing a red emitting thermostable 
mutant of P. pyralis luciferase. GE rate was evaluated in physiological conditions and 
following pharmacological stimulation or inhibition with drugs known to accelerate 
[31] or to delay [32] GE.  
 
MATERIALS AND METHODS 
Bioluminescent bacterial cells 
Competent E. coli strain JM109 (Invitrogen Corp., Carlsbad, CA, USA) were 
transformed with the plasmid pGex-6p-2 vector containing the red thermostable 
luciferase PpyRE8 mutant (GenBank, accession number GQ404465) under the 
control of Tac inducible promoter [33]. All reagents for bacterial cultures were 
obtained from Sigma (St. Louis, MO, USA).  
In vitro experiments 
Bioluminescence characterization of bacterial cultures. JM109 cells harboring pGex-
6p-2-PpyRE8 were grown from a single colony in LB broth medium with antibiotic 
selection (ampicillin 100 µg ml-1) at 37°C overnight and diluted in LB medium to 
midlog phase (A600nm 0.4). Cultures were induced with 0.1 mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) and incubated at 37°C in an orbital shaker for 1h until 
an A600nm of 0.6 or grown in the same conditions w/o IPTG. Bioluminescent emission 
of induced and non induced bacterial cells was measured with a LB 981 NightOWL 
imaging system (Berthold Technologies, Bad Wildbad, Germany). Briefly, 100 μL of 
bacterial suspension was imaged for 1 minute immediately after addition of 100μl of 
D-luciferin (Synchem, Felsberg, Germany) 1 mM in 0.1 M sodium citrate buffer 
solution at pH 5. Images were collected every minute for 60 minutes to monitor 
emission kinetics of the bacterial culture. Each experiment was performed in 
triplicate, and individual experiments were repeated at least 3 times. Spectra of 
bacterial cells were recorded with a Cary Eclipse fluorescence spectrophotometer 
(Varian, Palo Alto, CA, USA) using aliquots of E. coli cells expressing the red mutant. 
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Cells were grown at 37°C to A600nm 0.4, supplemented with 0.1 mM IPTG to induce 
luciferase expression, and incubated for 2 h at 37°C. Samples were collected, and 
the A600nm was adjusted to 0.9 using LB. Aliquots (200 µL) were transferred to a 1 mL 
cuvette, a 400 µL of PBS solution at pH  3.0, 4.0, 5.0 and 7.0 (adjusted with 
hydrochloric acid when necessary) was added together with 200 µL of 1 mM D-
luciferin at pH 5.0 to mimic the in vivo model. 
Preparation of bioluminescent cell suspension for oral administration. A 5 ml 
overnight  culture of E. coli harbouring pGex-6p-2-PpyRE8 was diluted in 20 ml of 
fresh LB broth and grown at 37°C to A600nm 0.4, then supplemented with 0.1 mM 
IPTG to induce luciferase expression and incubated at 37°C to A600nm 0.8. An aliquot 
(200 µL) of cell culture was mixed 1:1 with D-luciferin solution 1 mM in 0.1 M sodium 
citrate buffer solution at pH 5.0; this 400µl mixture (containing 1.8x 108cells) was 
called “bioluminescent microbead suspension” and was prepared fresh for every 
imaging session. 
 
In vivo studies 
Animals. All experiments were approved by the Ethical Committee of the University of 
Bologna. A total of 51 male Balb/c mice (6 weeks old, 20-25 g/body weight) (Charles 
River, Calco, Milan, Italy) were used for a total of 141 experiments. The animals were 
housed 2 weeks before the experiments and fed the usual commercial diet and water 
ad libitum. They were kept at constant light/dark cycling throughout the study in wire-
bottom cages and the experiments were started at 9 a.m. Mice were kept in wire 
bottom cages in the 18 hours previous to the experiments (one each cage) and after 
the experiments they were moved to solid bottom cages (3 each cage). 
Determination of gastric emptying by bioluminescence imaging. The day of the 
experiment, after i.p. injection of Zoletil (Tiletamine and zolazepam 20 mg Kg-1 b.w., 
Virbac Laboratories, Carros, France) the animals were given 400 µL of the 
bioluminescent microbead suspension by oral gavage using a stainless bulb tipped 
gavage needle (20 gauge) (Instetech Solomon Inc, Plymouth, PA, USA). For fed 
mice, anaesthesia was given immediately after food ingestion and was effective 
within 5 minutes of the i.p. administration and lasted over 30-40 minutes. The 
imaging was performed using the LB 981 NightOWL imaging system linked to a PC 
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running WinLight 32 software (Berthold Technologies).  Imaging began 15 min after 
the addition of D-luciferin to bacterial solution. Signal intensity was quantified as the 
flux of all the detected photon emissions within the region-of-interest (ROI) of the 
mouse body. Three animals were used to evaluate loss of signal due to skin and 
abdominal wall absorption by imaging before and after opening the abdomen. The 
grey-scale photograph of the mice obtained in the specimen chamber under 
illumination was overlain with a pseudocolor luminescent image showing spatial 
distribution of the emission. Data were expressed as photons/s/pixel. Since no 
significant differences in photon flux were recorded in different selected areas drawn 
inside the animal or outside of the animal, the background photon flux was defined 
from a ROI of the same size placed outside the animal. These figures were 
subtracted from the photon flux in each region to quantify relative luciferase activity 
as a measure of the amount of bacteria. Reproducibility of the model was 
investigated using 3 mice. After anesthesia, the animals were given the biomicrobead 
suspension and imaging started immediately. GE imaging was performed in the 
same animal at 3 days intervals for a total of 3 determinations for each mouse to 
evaluate intra-animal variability. Inter-animal variability was determined comparing 
the T1/2 obtained from three different animals. 
Evaluation of gastric mucosal integrity after administration of BL bacteria. Increasing 
concentrations of bacteria (in the range 100-109 cells mL-1) were administered by 
gavage to 18 hours fasted mice to evaluate mucosal damage and/or inflammation. 
After the microbead suspension emptied from stomach into duodenum, gastric and 
duodenal mucosa were exposed and the samples were embedded in paraffin for 
hystological analysis.  
In vivo evaluation of gastric emptying of the BL microbeads in fed versus fasting 
animals  A cross-over design was used, each animal was its own control. Six animals 
were allotted to each group: group A, fed animals (F) and group B, fasting animals 
(NF); at period 1, A and B animals were used for gastric emptying studies in 
respectively fed and fasting conditions; in period 2, they were crossed over, 
respectively group A was used in fasting and group B in fed conditions. A total of 10 
days elapsed between the two sets of experiments in order to return to conditions as 
far as possible similar to the previous ones (see Supporting Material 1). The animals 
(fed) were taught to eat the solid meal (100 mg Swiss Cheese, 0.36 Kcal, 28% fat, 
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27% protein, 5.4% carbohydrate) within 5 minutes of the administration.  Food was 
withdrawn 18 hours before the experiment and water was allowed ad libitum. The 
day of the experiment, group A received the solid test meal and both groups after 
anaesthesia were given 400 µL of the bioluminescent microbead suspension by oral 
gavage. 
Evaluation of gastric emptying of a solid meal in controls versus metoclopramide and 
hyoscine butylbromide treatment at different doses. Three groups of animals: C, D, E 
were used (6 animals each) respectively as controls (CON), metoclopramide (MET), 
and hyoscine butylbromide (HY) treatment. A cross-over study was adopted 
(Supporting Material 1 and 2).The wash-out time between each set of experiments 
was 10 days. Metoclopramide (Sigma) was dissolved in sterile water for injection to 
provide doses of 0.5-2.5 mg Kg-1. Hyoscine-N-butylbromide (Sigma) was dissolved in 
sterile water for injection to provide doses of 0.5-2.5 mg Kg-1. For the first set of 
experiments, 18-hours fasted mice were administered intraperitoneally either placebo 
(100 µL of saline solution) or metoclopramide (1 mg Kg-1) or hyoscine butylbromide 
(1 mg Kg-1) twenty minutes before the administration of the test. After eating, animals 
were anesthetized and 400 µL of “bioluminescent microbead suspension” were 
administered by oral gavage. Immediately after administration, the animals were 
imaged. Each animal was its own control: 3 groups of animals were studied (6 
animals each group): CON, MET and HYO. Then dose-response studies were 
performed. In the first group 100 µL of saline was administered according to the 
protocol above reported; in the MET group, metoclopramide (0.5, 1 and 2.5 mg kg-1) 
was administered in random order and similarly the HYO group received hyoscine 
butylbromide at the doses of 0.5, 1 and 2.5 mg Kg-1 in random order.  
 
Statistical analysis 
For every individual animal, the GE was determined as a function of time from the 
changes in total bioluminescent emission in the respective ROI, according to the 
formula 
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where Istomach is the integrated photon flux within the stomach and Itotal is the 
integrated photon flux within the region-of-interest (ROI) at each time point. For each 
animal, GE kinetics were described using a non linear regression analysis (sigmoidal 
Boltzman fit) [34] with Prism version 5.02 software (GraphPad Sofwtare, San Diego, 
CA, USA). The plateau asymptote was constrained to a value of 0. The gastric half-
emptying time, T1/2 defined as 0.5 GE%, was determined by interpolation. The 
goodness of fitting was evaluated by running a normality test (D‟Agostino-Pearson) 
on the residuals. Differences between treatment groups were conducted using one-
way ANOVA for multiple comparisons. All results are expressed as mean ± SEM, n= 
number of animals p<0.05 was considered statistically significant.  
 
RESULTS 
In vitro characterization of the bioluminescent probe The selected BL probe for GE 
evaluation is based on a luciferase mutant that has two important features that 
improve the performance of BL in vivo imaging: high thermostability at 37°C and 
emission in the red region of the visible spectrum. Different culture conditions were 
evaluated to obtain a standardized cell population with a stable steady-state light 
emission after substrate addition in the temporal window of GE imaging session. 
Bacterial cultures were induced with IPTG to increase luciferase expression and the 
identified optimal temporal window was 20 minutes; BL signal remained stable for at 
least 1 hour (Figure 1). The effect of pH on PpyRE8 BL intensity and spectrum was 
also evaluated. As shown in Figure 2.A., at different pH the normalized BL emissions 
of PpyRE8 showed an unchanged spectrum with λmax 614 nm [33]. On the contrary, 
the green emitting wild-type luciferase shows a red-shifting and reduced intensity at 
low pH; this could introduce a bias during imaging of GE since red light is less 
absorbed and scattered by biological tissues. The kinetic profile remains unchanged 
with two emission maxima, one after substrate addition and the other after 25±1 min 
after substrate addition (Figure 2.B).  
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Figure 1: Emission kinetics of JM109 E. coli bacterial cultures expressing the PPyRE 8 luciferase 
under the regulation of a strong IPTG inducible tac promoter after D-luciferin 1mM addition with or 
without IPTG induction.  
 
 
Figure 2: Normalized emission spectra of the “bioluminescent microbead suspension” obtained by 
mixing bacterial cells expressing PPyRE 8 with D-luciferin at pH 5.0 and a fixed volume of PBS 
solution at different pH to mime the stomach conditions. Spectra were recorded immediately after D-
luciferin addition (2.A). Emission kinetics of the “bioluminescent microbead suspension” at different pH 
(2.B).  
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Determination of GE . The method includes the acquisition of images of the live 
animal after oral administration of the BL microbeads and BL substrate. Performing 
repeated bioluminescence image acquisitions on mice was very feasible. The loss of 
signal due to absorption by skin and abdominal wall was 78%±5, as calculated in 
Material and Methods section. However, this did not prevent a reliable localization 
and quantification of the signal. A light anaesthesia with Zoletil was selected to keep 
the animal still under the CCD imaging device thus avoiding animal handling during 
the GE monitoring. The high signal-to-noise ratio of bioluminescence allowed to 
define and draw the ROIs corresponding to the stomach area (Figure 3). GE was 
clearly assessable on sequential images were the microbeads are released in the 
duodenum and along the entire intestine (see Supporting Material 3). The basal T1/2 
evaluated with three separate experiments using the same animal was 17±2 min and 
the basal T1/2 of three animals was 17±4 min, thus demonstrating a good 
reproducibility.  
 
Figure 3: Gastric emptying imaging of fed and non-fed mice using the “bioluminescent microbead 
suspension”. Images were collected every 3 min with exposure time 1 min from 5 to 30 min after food 
ingestion. A T1/2 of 16±3 min has been calculated for the administered solid meal.  
 
Evaluation of mucosal integrity after administration of BL bacteria. The oral 
administration of bacterial suspensions did not lead to any alteration in the mucosa 
either in the stomach or in the duodenum. No signs of acute flogosis were apparent. 
The absence of luminescence from the stomach mucosa and microscopy evidence 
demonstrated that bacteria did not adhere to the stomach (data not shown).  
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In vivo evaluation of gastric emptying in fasting versus non-fasting conditions. In 
fasting conditions, luminescent bacteria appeared simultaneously in the stomach and 
in the duodenum area, indicating that GE  was immediate, consistent with data 
reported in literature of GE of water [35].In fed animals, after a test meal was given, 
GE was significantly slower (T1/2 16±3 min) than that obtained in fasting conditions 
(T1/2 2±1 min). Results were similar before and after the wash out period (10 days), 
indicating both complete return to the initial conditions and reproducibility of the 
method (Figure 3). 
In vivo evaluation of GE of a solid meal in controls versus metoclopramide and 
hyoscine butylbromide at different doses. 
 In control mice, basal T1/2 was 17±4 min; administration of hyoscine butylbromide (1 
mg Kg-1 b.w.) significantly (p<0.05) increased T1/2 that was delayed up to 25±4 min; 
on the contrary, metoclopramide (1 mg Kg-1 b.w.) significantly (p<0.05) accelerated 
T1/2, that was achieved within 8±2 min. BL imaging of mice control-metoclopramide-
hyoscine butylbromide 1 mg Kg-1 is shown in Figure 4.  
 
 
Figure 4: Gastric empting imaging of control mice or treated with metoclopramide (1 mg/kg b.w.) or  
hyoscine butylbromide (1 mg/kg b.w.) using the “bioluminescent microbead suspension”. Images 
collected every 3 min with exposure time 1 min from 5 to 30 min after food ingestion. In control mice, 
basal T1/2 was 17±4 min; in mice treated with metoclopramide  T1/2 was 8±2 min while in mice treated 
with hyoscine butylbromide was 24±5. 
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Dose-dependent effects of hyoscine butylbromide and metoclopramide on GE are 
shown in Figure 5. Gastric-emptying curves in fed mice treated with saline solution, 
metoclopramide 1 mg Kg-1 or hyoscine butylbromide 1 mg Kg-1 obtained from four to 
eight mice and the regression lines resulting from modelling the data to a sigmoidal 
Boltzman function are shown in Figure 6.  
 
Figure 5: Graph representing T1/2 variation in mice treated with different doses of metoclopramide or 
hyoscine butylbromide resulting from cross-over study.  Data represent the mean ± SEM. 
 
 
Figure 6. A. Gastric-emptying curves for fed (T1/2 16±3 min) vs fasted mice (T1/2 2±1min). 6. B. 
Gastric-emptying curves in fed mice treated with saline solution (T1/2 17±4 min), metoclopramide 1 
mg/kg (T1/2 8±2 min) or hyoscine butylbromide 1 mg/kg (T1/2 24±5 min). Drugs were administered 
intraperitoneally 20 min prior to meal. Each curve represents mean results (± SEM) obtained from four 
to eight mice. Also shown  are the regression lines (red lines)  resulting from modelling the data to a 
sigmoidal Boltzman function.  
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DISCUSSION  
Choice and characterization of bioluminescent bacteria as GE probe We envisaged 
the possibility to use bioluminescent non-pathogen bacteria as self-luminescent 
microbeads. Bacteria are a low cost, easy to prepare, dispersed suspension of 
micrometer size beads that, after mixing with gastric content, can be used as a 
marker for GE studies. The advantages of bacterial microbeads were combined with 
reporter gene technology to develop a probe that, by means of in vivo imaging, 
provides a real time visualization of gastric content release into the duodenum. To 
characterize and standardize the model, in vitro studies were performed to 
investigate variations in bioluminescence emission intensity, wavelength and kinetics 
according to different pH conditions that are present in the gastrointestinal tract. 
Since green light is more absorbed and scattered by biological tissues, we selected a 
red-emitting probe (PPyRE8, a mutant of P. pyralis luciferase with λmax 615 nm) to 
improve the performance of in vivo bioluminescence imaging in terms of sensitivity 
and spatial localization. This allowed an easier definition of ROIs than near 
Reflectance Imaging models, that in addition suffers from fluorescence emission 
background [34]. Besides, the selected luciferase mutant has very good 
thermostability (half-life at 37°C of 3.5 hrs vs 0.26 hrs of wild type luciferase), its 
emission is stable at different pH and its emission kinetics provide a stable and high 
BL signal during GE monitoring .This stability in terms of emission wavelength and 
intensity is very important for the reproducibility and sensitivity of the model to avoid 
misinterpretation of results due to variations in pH along the gastrointestinal tract.  
Safety and stability of the BL microbeads. A prerequisite of a marker of GE is that it 
should not lead to gastric mucosal damage: the stomach which is in continuous 
contact with host microbial population has evolved an array of strategies for 
preventing bacterial invasion into deeper tissues. The pH of the stomach of mice is 
about 3 and 4 respectively in fed and fasting conditions and in the duodenum about 
4.9 and 4.7, respectively in fed and fasting conditions. Bacteria survive within a range 
of pH between 3.0 and 6.0 [36, 37] and similarly the bioluminescent emission 
produced by the mutant luciferase inside bacteria is stable within this range. It should 
be pointed out that the introduction of bacterial cells in the stomach, an environment 
highly different from the laboratory culture conditions make them return to a lag 
phase. Since they are adapting to a new environment we assumed they do not 
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replicate during imaging session. Besides, endoluminal conditions such as oxygen 
content, number of bacteria and distance from the surface of light-emitting bacteria 
were taken into consideration for developing the model. These factors mostly affect 
the bioluminescent imaging in the duodenum, which is deeper and poorer in oxygen 
than the stomach. Nevertheless after 180 min bacteria present in the colon area still 
emit light (data not shown) and, with CCD with improved sensitivity, the complete 
intestinal transit process  can be easily visualized. The use of living bioluminescent 
bacteria that continuously produce light provides a non toxic GE probe that emits 
light without the need for external light source. Other probes, such as self-illuminating 
quantum dots, cannot be used due to their in vivo toxicity. 
GE bioluminescence in vivo model. The suitability and reliability of this technique to 
study gastric emptying is demonstrated by the fact that the bioluminescent signal is 
easily detected, visualized and analyzed. Furthermore the measurements obtained in 
different experimental conditions were consistent with each other. The microbeads 
empty from the stomach with a similar pattern in the same animal over time, and 
different animals show similar emptying rate. Thanks to their micrometer size (far less 
than 1 mm, the diameter of mouse pylorus), hydrodynamic properties and negligible 
caloric content (9 calories), bioluminescent bacteria cells mimic non nutrient liquid 
emptying. This finding confirms the results obtained by Zhao et al., who monitored by 
optical imaging the progress of Escherichia coli-GFP through the mouse 
gastrointestinal tract [38]. Differently from our model, which is based on oral gavage 
of  1.6 x 108 cells, they gavaged immunodeficient mice with 1011 cells to induce 
infection; in agreement with us they reported that stomach in non fed mice emptied 
within 10 min after gavage. In fed animals, the emptying rate is delayed  due to 
mixing of the bioluminescent probe with the gastric content. This indicates that the 
bioluminescent bacteria can be considered indeed, as a probe to monitor the GE 
process. The present model has been also demonstrated to be sensitive enough to 
discriminate among pharmacological modulations of the GE: the prokinetic agent 
metoclopramide dose-dependently accelerates gastric emptying, while hyoscine 
butylbromide delays GE, in agreement with a previously published GE model based 
on optical imaging [34]. In the setting up of the model some variables were carefully 
considered, among which the meal, handling of the animal, and anaesthesia. A solid 
meal was preferred over a liquid one because it is more physiological and 
spontaneously eaten by the animals, allowing the best evaluation of the physiological 
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mouth to duodenum progression of the food and reducing the stress of the 
administration. The choice of a solid standard meal was also prompted by the 
necessity of reducing to a small volume, not exceeding 400 μL, the total volume of 
the bacterial medium and the liquid formula. The administration of a higher volume 
can lead to a painful distension of the small stomach of the animal and the reduction 
to a smaller volume could increase the viscosity of the formula, making difficult its 
administration through the small cross sectional diameter of the feeding needle (20 
gauge). After 18 hours fasting, trained mice ate spontaneously and rapidly within 5 
minutes of the administration of food. BL microbeads were not added to the food 
since mice didn‟t eat the mixture spontaneously and it took them more than 15 
minutes to complete food ingestion. The subsequent immediate administration of the 
bacteria by oral gavage allowed the standardization of the starting time for imaging. 
As far as anaesthesia, since high doses of the commonly used isoflurane delay GE in 
animals and man [39], we have used a combination of zolazepam and tiletamine [40], 
to obtain a very light sedation of the animal sufficient to make it rest in the dark 
camera. Handling of the animals has been reported to be a moderate stress inducer 
thus altering GE therefore, once put in the camera, the animals were not moved 
throughout the whole GE monitoring. It was possible to take acquisitions every three 
minutes, resulting in enough time points for tight-fitting algorithms. The developed 
model thus combines a short monitoring interval, as breath test-based GE models 
with the possibility of visualizing the whole GE process and obtain quantitative data 
as with imaging techniques. Furthermore, the model does not require the use of 
radiopharmaceuticals as scintigraphy or MRI. Compared to a recently reported X-ray 
GE model that measures stomach volume as parameter to evaluate GE two weeks 
after the implantation of a gastric fistula, our model is much easier and rapid to 
perform, moreover there is no need for surgery on the animal and to employ ionizing 
radiations. Nevertheless, the method can not be used in intestinal inflammation 
studies because the presence of bacteria could increase the severity of inflammation. 
A drawback of the model is the need to induce sedation to mice, but this allows to 
keep the animal still for image acquisition. Alternatively, the model could be applied 
to non anaesthetised freely moving animals with a recently reported new imaging 
system [41] . Therefore, the model is a promising imaging tool in drug development 
and can be proposed in pre-clinical tests in pharmaceutical research and for 
pathophysiological studies (e.g., diabetics gastroparesis). Besides, we can extend 
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this model to other rodent species [42] and to transgenic animals (e.g., models of 
obesity and diabetes). Since an analogous photoprotein has been commercialized as 
a dietary supplement it is conceivable, in a near future, the use of an encapsulated 
formulation of purified luciferase-substrate as self-luminescent probe for GE 
monitoring in humans with non invasive bioluminescence imaging.  
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Supplementary Material 
Supporting Material 1: Design of experimental protocol. A cross-over design was used. A total of 6 
animals were allotted to each group: group A: fed animals(F] and group B: fasting animals (NF]. 
 
Supporting Material 2: Table of the experiments.  
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Abstract 
 
Background: Despite a plethora of bioluminescent (BL) reporter genes being cloned and 
used for cell assays and molecular imaging purposes, simultaneously monitoring of multiple 
events in small animals is still challenging. This is due in part to the lack of optimization of the 
cell expression and spectral resolution of the used color-coupled reporter genes. A new red 
emitting codon-optimized luciferase reporter gene mutant of Photinus pyralis, Ppy RE8 has 
been developed and used in combination with the green click beetle luciferase, CBG99 for in 
vitro and in vivo dual color imaging applications.  
Principal findings: Human embryonic kidney cells (HEK293) were transfected with vectors 
expressing red Ppy RE8 and green CBG99 luciferases. Populations of red and green 
emitting cells were mixed in different ratios. After addition of the shared single substrate D-
luciferin, BL signals were imaged with an ultrasensitive cooled CCD camera using a series of 
band pass filters (20nm). Spectral unmixing algorithms were applied to the images obtaining 
a good separation of signals. Then, HEK293 cells expressing the two luciferases were 
subcutaneously injected in living mice achieving a reliable imaging and quantification of both 
BL signals in mixed population of cells. These results demonstrated for the first time the in 
vivo molecular imaging of two simultaneous BL signals after the injection of the same 
substrate (D-luciferin). 
Significance: The applicability of Ppy RE8 firefly luciferase in combination with CBG99 click 
beetle luciferase was demonstrated both in vitro and in vivo. In respect to previously used 
dual assays, the present one combines a greater sensitivity thanks to an efficient cell 
expression with an adequate BL spectral resolution using a suitable algorithm for spectral 
unmixing. This new D-luciferin-dependent reporter gene couple opens up the possibility to do 
more accurate quantitative gene expression studies in vivo by simultaneously monitoring two 
events in real time. 
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Introduction 
 
During the last decade, bioluminescent (BL) imaging has become an indispensable tool for 
visualizing molecular events at a cellular level both in vivo and in vitro leading to new 
advances and discoveries in life sciences1. There are many available BL luciferase/luciferin 
reporter gene systems for in vivo imaging: the first used and most popular are the luciferases 
that require D-luciferin and are ATP dependent (i.e. firefly luciferase, click beetle luciferase).  
Other luciferases such as Renilla luciferase and Gaussia luciferase that require 
coelenterazine as a substrate and are ATP independent are nowadays also used2,3. In 
addition, the use of the blue emitting(490nm) bacterial luciferases from P. luminescens have 
been reported4. Such luciferases do not require the infusion or administration of the BL 
substrate but are scarcely expressed in mammalian cells.  The codon-optimized version of 
this luciferase has been recently proposed for in vivo imaging but cannot compete yet with 
firefly luciferase performance5. Renilla and Gaussia luciferases emit blue light which in part 
compromise their in vivo performance due to extensive light absorption by the small animal 
body. Blue light is strongly absorbed by tissue components particularly in highly vascularised 
tissues where haemoglobin is present6. In the case of Renilla, new red shifted and more 
stable mutants with an emission peak at 535 or 547 nm have been produced7 by site directed 
mutagenesis, but dual color imaging still remains difficult to perform due to the relative low 
quantum efficiency of CCD cameras below 500 nm (30%) where the native enzyme shows 
the peak of emission. Until now there are no red shifted Gaussia luciferase mutants available 
but only brighter ones or with a prolonged half-life 4,8,9. Red-emitting mutants from the railroad 
worm (Phrixothrix hirtus) with higher activity and better stability have been recently proposed 
for bioluminescence imaging but not fully studied for in vivo applications10. Regarding click 
beetle and firefly luciferases, variants with different emission wavelengths have been 
developed but still lack of optimal characteristics for in vivo imaging11,12. In particular, 
red/green couples of reporter proteins for in vivo applications must possess intense BL 
emission with narrow emission spectra resulting in a reasonable separation and with good 
thermostability at 37°C12,13,14. Codon-optimization of the reporter gene is a fundamental 
prerequisite for improving the BL signal in mammalian cells thus facilitating their detection in 
vivo15. Recently it has been reported that dual color BL imaging could be applied in vitro 
using appropriate filters for the separation of BL signals and mathematical corrections for 
their deconvolution16,17. Furthermore, in vivo applications using multicolor analysis can be 
achieved using different substrates or fluorescent proteins18. For a simultaneous in vivo 
detection of the fate of two set of cells here we report the use of a novel red codon-optimized 
luciferase reporter gene mutant of Photinus pyralis, Ppy RE8, combined with the green click 
beetle luciferase, CBG99.  Ppy RE8 is characterized by a peak emission at 618 nm and has 
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an excellent thermostability (half-life of 4,5h at 37°C)13.  CBG99 is a pH insensitive luciferase 
with an emission maximum at 537 nm which showed better performance for in vivo 
applications than the widely used Photinus pyralis wild type luciferase (PpyWT)19. Here , we 
demonstrate the applicability of the two luciferases in vitro and in vivo by generating lentiviral 
vectors for the expression of the genes under the control of the CMV promoter. Multicolor 
HEK293 cell based assays were developed to evaluate the suitability of simultaneous 
measurements of the red and green emitting luciferases by spectral unmixing. Both 
luciferases maintained the same spectrum of emission in cells at 37°C. We also show the 
applicability of the dual luciferases in vivo when HEK293 cells were inoculated 
subcutaneously in mice and imaged after intraperitoneal injection of D-luciferin. A good 
separation of the individual signals could be obtained using spectral unmixing algorithms for 
their deconvolution. Ppy RE8 was demonstrated to be an excellent tool for in vivo BL imaging 
and, in particular, when used in combination with a green luciferase to monitor dual events at 
the molecular level. The use of a single D-luciferin substrate for the same couple of reporter 
gene allows time and cost saving in contrast to dual-color luciferase imaging using Firefly and 
Renilla luciferases in which the addition of a second luminescent substrate, coelenterazine, 
is warranted. 
Results  
 
Emission spectral unmixing of bioluminescence in cell lysates 
To evaluate the ability of the two red and green selected luciferase signals to be detected 
and quantified in a single run analysis using a single substrate, the red codon-optimized 
luciferase reporter gene Ppy RE8 and the green emitting click beetle CBG99 were expressed 
transiently under the control of the same promoter in HEK293 cells and lysed after 24 hours. 
For the same number of cells the light output of red emitting lysate was 2.5 higher than the 
one of green emitting cells (Fig 1A). This is expected since, as previously reported, CBG99 
is as bright as CBred but with more stable emission kinetics11. Ppy RE8 has been reported to 
generate more luminescent signals than CBred in a cell-based assay13. Moreover, when cell 
lysates of the red or green expressing cells were plated in different ratios, calculations of the 
percentages of red and green light in a mixture were possible by applying the spectral 
unmixing algorithm to the acquired images (images acquired using a series of 20nm band 
pass filters) as shown in Figure 1B. In this set of experiments there were no significant 
differences between plated and calculated percentage of cell lysates demonstrating the 
validity of the method. In addition, the algorithm allowed calculating the emission spectra for 
both luciferases and Ppy WT, which were similar to those obtained when analysed 
separately (Fig. 1C). A representative image of a spectral unmixing of cell lysates is shown 
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in Figure 2. Lysates from red and green expressing cells were serially diluted in duplicate 
and mixed in different proportion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Validation of Ppy RE8 and CBG99 as a bioluminescent couple for multicolor 
imaging.(a) Level of expression of lentiviral constructs in Hek293 cells. (b) Spectral unmixing 
of cell lysates mixed in different proportions. Cells were lysed 24 h after transfection with 
lentiviral constructs. (c) Emission spectra of luciferases calculated with Living Image software 
in cell lysates at 25°C with the Ppy RE8 peak around 620 nm, CBG99 around 540 nm and 
WT Luc around 560 nm. 
 
Live cell dual color imaging 
This set of experiments was carried out on HepG2 cells to evaluate the performance of this 
pair of luciferases in living cells. Selected clones of cells stably expressing the luciferase 
variants can not mirror the expression level of transiently transfected populations, and 
different promoters vary expression in different cells types. For these reasons a direct 
comparison between the level of expression of CBG99 and Ppy RE8 luciferase cannot be 
performed but other relevant parameters such as emission spectra and dynamic range of 
luminescence signals for in vivo application can be evaluated. Ppy RE8 expressing cells 
showed a 5-fold higher signal than the cells expressing CBG99 at 37°C. A good correlation 
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between number of cells and light emission was obtained (R2 =0.98) (Fig 3). Moreover the 
emission spectrum of Ppy RE8 cells did not vary in cells at 37°C.  
 
 
Figure 2 Representative image of emission spectral unmixing of bioluminescence in cell 
lysates.(a) Multispectral acquisition of red and green emitting cell lysates. In the left part (row 
1 and 2)) of the plate dilutions of green emitting lysates were dispensed in duplicate while in 
the right part (row 5 and 6) dilutions of the red ones. In the middle (row 3 and 4) lysates were 
mixed in different proportions. The plate was scanned with an open filter and at different 
wavelengths ranging from 500 nm to 680 nm with a 20 nm interval. 
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Figure 3 Live cell imaging. Representative spectral unmixing of signals emitted from stable 
red and green HepG2 cells; 105, 7.5 x 104, 5 x 104 and 2.5 x 104 cells were plated for each 
HepG2 cell line. 
 
 
In vivo dual color imaging  
In order to test this pair of luciferase for in vivo applications, cells expressing each 
luciferase were injected subcutaneously in mice. Five minutes after substrate 
injection, a series of images with 30sec aquisitions were obtained. The emission 
spectra of luciferases calculated from the in vivo experiments showed a slight red shift 
because of absorption and scattering of light generated under the skin (Fig. 4A). Intensity of 
the BL signals allowed the calculation of the red/green cell ratio in a mixed population 
after applying spectral unmixing algorithms. Average luminescence expressed in 
photon/sec/sr/cm2 was determined for the ROI corresponding to the different areas 
where cells were inoculated. These values were extracted from the unmixed images 
generated by Living Image software. Experiments carried out in three mice for both 
independent set of experiments gave reproducible results. The injected cells were 
105 and 2.5 x 104 in the mixture, and the calculated numbers of cells were 2.0 ± 0.4 x 
104 for CBG99 and 2.4 ± 0.2 x 104 for Ppy RE8 (Fig. 4B).  
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Figure 4 Multispectral acquisition of light from live animal. (a) Cells expressing Ppy RE8 and 
CBG99 luciferases and a mixture was inoculated in the upper part, middle part and lower 
part of the back, respectively. Emission spectra of luciferases calculated from the same in 
vivo experiments.  A slight red shift was noticed for both luciferases. (b) Unmixed and 
composite images. The injected cells were 105 and 2.5 x 104 in the mixture. The numbers of 
cells calculated with Living Image software were 2.0 ± 0.4 x 104 for CBG99 and 2.4 ± 0.2 x 
104 for Ppy RE8.  
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Discussion 
The main advantages of using bioluminescence in bioanalysis are related to the high 
signal/noise ratios and quantum efficiencies of the luciferin/luciferase system allowing 
to achieve an extreme high detectability in cell based assays and for in vivo 
molecular imaging20,21. Moreover, the availability of luciferases with different emission 
wavelengths gives the possibility of performing multicolor and multiplexed assays. 
Here, we evaluated for the first time a new red-codon optimized luciferase Ppy RE8 
in combination with a green click beetle CBG99 luciferase that permitted a 
simultaneous, sensitive and reliable 2D imaging and quantification of different 
imaging signals in vivo using the same D-luciferin substrate. Issues concerning in 
vivo applications like tracking cells in deep tissues are different from that concerning 
analysis of gene expression in cell based assays. For this reason we carried out 
experiments in three different conditions: in cell lysates, in live cells and in whole 
animals. In order to demonstrate its performance we employed the Ppy RE8 and 
CBG99 genes for the development of lentiviral expression vectors and used them for 
transient and stable expression in different cell lines. A major concern was to 
separate the green emission overlap with the red filter (620 nm) particularly when the 
two signals have a different intensity. Images were obtained by collecting light using 
a set of filters (20 nm band pass) from 500 nm to 680 nm and without a filter. This 
was performed on the IVIS Spectrum (CaliperLS Inc, Hopkinton, MA) and a spectral 
unmixing algorithm was applied to all the images (Living Image 4 software, 
CaliperLS, Inc). The spectral unmixing of the images obtained from cell lysates 
showed the suitability of the use of these red and green luciferases as a BL pair with 
a single substrate. Images were collected five minutes after substrate addition when 
signals of both emitting enzymes are stable as indicated by previous studies11,13. 
Then, we performed analysis on stable transfected HepG2 cells to mimic the 
conditions for in vivo imaging. In this case, temperature was set to 37°C and the 
substrate consisted of 1mM D-luciferin without cofactors normally present in 
commercial assay buffers for testing cell lysates. Each image generated by a 
different band pass filter of 20nm was obtained by integrating signals for 30 s since 
ATP present in living cells represents a limiting factor on bioluminescence intensity. 
In this set of experiments, acquisition of images requires 5 minutes and detection and 
quantification of signals were accurate. Moreover, we envisage the possibility to 
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perform single cell or tissue analysis by using a novel implemented microscope for 
dual color bioluminescence imaging22,23. 
Finally, we evaluated the pair of luciferases in living animals and reinforce the 
concept that this pair of luciferases is optimal for in vivo imaging. Our results from 
living mice inoculated with red and green emitting cells demonstrated the possibility 
to 2D visualization and (semi-)quantification of cells emitting different colors in mixed 
populations. The light emission of both luciferases underwent a red-shift of 20 nm 
due to tissue absorption and scattering of light generated under the skin. As 
previously reported24, emission spectra of luciferases in vivo show dependence from 
tissue depth and composition due to absorption and scattering of light through 
tissues. Therefore, the use of the red emitting enzyme is preferential for imaging in 
deeper tissues. Moreover, future improvement of the analytical performance of 
spectral unmixing of light signals as in fluorescence applications should lead to a 
better separation in deeper tissues25. Recently, Hida and colleagues applied 
multicolor luciferases to study protein-protein interaction and proposed Phrixothrix 
hirtus red luciferase (em. Max. 630nm) as an internal control in combination with 
fusion proteins constructed of different N or C parts of luciferases for a 
complementation assay. However, no multispectral image acquisition was performed 
and no unmixing algorithm was applied to images in order to obtain effective 
quantification of signals in vivo26.In conclusion, Ppy RE8 was demonstrated to be an 
excellent tool for both in vitro and in vivo bioluminescence imaging and, in particular, 
when used in combination with a green luciferase to monitor dual events at the 
molecular level. Ppy RE8 has a good thermostability at 37°C and is highly expressed 
in mammalian cells. Differently from the use of click beetle luciferase as a green 
counterpart, the combined use of Firefly and Renilla luciferase requires the use of 
different substrates that are luciferin and coelenterazine. Biodistribution and enzyme 
kinetics with the two substrates are very different making ratio-metric measurements 
more difficult. Therefore, the described new D-luciferin-dependent red/green couple 
will allow to perform better (semi-) quantitative gene expression studies in vivo and 
will enable simultaneous tracking of different populations of stem cells, T-cell 
accumulation in tumor and simultaneous analysis of different molecular pathways. 
Finally, new dual color transgenic animal models may be generated. 
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Materials and Methods 
 
Ethics statement 
Animal experiments were approved by the Bioethics Committee of Leiden University, 
the Netherlands in compliance with international guidelines. 
Plasmid construction 
Self-inactivating lentiviral vectors, pLV.CMV.bc.NEO and pLV.CMV.bc.PURO, were kindly 
provided by Prof. R. Hoeben.  The pLV.CMVPpy RE8.NEO vector was constructed by 
amplifying the Ppy RE8 gene from pGex Ppy RE811, using the following pair of primers: Ppy 
RE8ForAscI: taggcgcgccgaggacgccaagaacatca and Ppy 
RE8RevXhoI:aatctcgagtcagatcttgccgcccttctt, and inserted in the MCS of pLV.CMV.bc.NEO. 
pLV.CMVCBG99.PURO was created by inserting the CBG99 gene, cut with NcoI and XbaI 
from the pCBG99basic vector (purchased from Promega, Madison,WI, USA), into the MCS 
of  pLV.CMV.bc.PURO via blunt ligation. 
Cell lines  
HEK293 and HepG2 cells were cultured in DMEM (Sigma, St. Louis, MO, USA) with 10% 
fetal bovine serum and 2 mM L-glutamine. The cultures were incubated at 37°C with 5% 
CO2. HepG2 cells were transduced by self-inactivating lentiviruses as previously described
27. 
Cell clones were selected with 1 mg/ml G418 or 1 μg/ml Puromycin for 14 days. 
Imaging  
All images were acquired with an IVIS spectrum (Caliper Life Sciences, Hopkinton, MA, 
USA) with the stage heated to 37°C during live cell imaging. The plates used were black-
walled with clear bottoms. Generally, images were acquired at binning 8x8 pixels, f/stop 1, 
12.5 cm field of view for the time and with the filter sets indicated. Experiments carried out 
with a different setup are indicated. Living Image 4 software was employed for generating 
spectral unmixed images and calculations of signals. 
Spectral unmixing of emission wavelengths in cell lysates  
Confluent HEK293 cells from a T25-flask were trypsinized and 105 cells/well plated in a 6 
well plate. The next day, cells were transfected with 1 μg of pLV.CMVPpy RE8.NEO or  
pLV.CMV.CBG99.PURO using Fugene HD, per the manufacturer‟s protocol. After 24 h, cells 
were lysed for 10 min with 0.4 ml of Promega‟s Passive lysis buffer. Cell debris was pelleted 
by centrifugation at 13,000 rpm for 10 min. The level of expression of each luciferase was 
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evaluated in triplicate, and then each luciferase was diluted to a similar level of activity in 
lysis buffer. Subsequently, 30 μl of each lysate were plated in linear dilutions and in different 
proportions and imaged after addition of 30 μl of luciferase assay buffer (Promega, Madison, 
WI,USA) in a 96 black-walled plate with a clear bottom. Images were taken using a set of 20 
nm filter steps from 520 nm to 680 nm and without a filter: acquisition time was 2 sec and 
f/stop 4 at 25°C. Two independent sets of transfections and images were used for 
calculations. Green and red signals were calculated from unmixed images. Data were plotted 
using GraphPad Prism 5. 
Spectral unmixing of emission wavelengths in living cells  
Stably expressing red and green HepG2 cells were trypsinized and resuspended in PBS in 
the 96 black-walled plates described above. Images were acquired at 37°C 5 min after 
addition of 1 mM D-luciferin (Synchem OHG, Felsberg, Germany) for 5 sec. Three 
independent experiments were carried out using the same selected cell lines.  
In vivo imaging in mice 
HEK293 cells were plated at 2 x 105 cells per well in a six well plate. After 24 h, 1 μg of either 
pLV.CMVPpy RE8.NEO or pLV.CMVCBG99.PURO was transfected as described.  After 24 
h, the cells were trypsinized, pelleted and resuspended in PBS at 105 cells/100 μl. Aliquots 
were used for testing in vitro and in vivo imaging in mice. Athymic mice (BALB/c nu/nu, 4-6 
weeks old) mice were acquired from Charles River (Charles River, L'Arbresle, France),  
housed in individually ventilated cages while food and water were provided ad libitum.  Mice 
were anesthetized by isofluorane, while injected subcutaneously with cells. Images were 
acquired 10 min after i.p. injection of D-Luciferin (150 mg/kg) using 30 sec exposure with or 
without filters. Two independent sets of transfections were performed for each of which three 
mice were tested. 
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Abstract 
Bioluminescent (BL) proteins are a promising tool for diverse applications based on reporter 
gene technology thanks to their high sensitivity and range of linear response. Due to their 
widespread use in the environmental, medical and agro-food fields, there is a great need for 
new BL reporter proteins with improved characteristics to provide researches a wide range of 
suitable reporters. Few efforts have been made in this direction and further improvement of 
BL reporters features (e.g., thermostability, narrower emission bandwidth, emission at 
different wavelengths) tailored for specific applications would be a remarkable progress 
toward the development of ultrasensitive multiplexed assays either in vitro or in vivo. The 
suitability of using red- and green-emitting thermostable mutants of Photinus pyralis firefly 
luciferase and two click beetle luciferases in combination with a secreted luciferase from 
Gaussia princeps was evaluated to develop a triple-color mammalian assay. Two triple-
reporter model mammalian systems were developed in a human hepatoblastoma cell line to 
monitor the transcriptional regulation of cholesterol 7-α hydroxylase (cyp7a1), the enzyme 
that catalyzes the first and rate-limiting step of the main pathway responsible for cholesterol 
degradation in humans. These model systems allowed us to evaluate the feasibility of using 
two intracellular BL reporters and a secreted one in the same cell-based assay. The 
selection of reporter proteins characterized by similar expression levels was identified as a 
critical point for the development of a multicolor assay.  
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Introduction 
Genetically engineered cells (bacteria, yeasts or mammalian cells) able to produce a 
bioluminescent (BL) signal in response to the target analyte represent an interesting 
approach for environmental, medical and food analysis with the great advantages of 
low cost, rapidity and sensitivity.1,2 A peculiarity of these analytical devices resides is 
their ability to measure the bioavailable fraction of the analyte, which is a crucial 
information difficult to obtain with other analytical techniques. The cells are modified 
by introducing a reporter gene fused to a regulatory DNA sequence that is activated 
only in the presence of the analyte (e.g., genotoxic compounds, oxidants, metals, 
hormones, organic xenobiotics) thus regulating the reporter gene expression. Several 
whole-cell biosensors and cell-based assays have been developed by employing BL 
reporter genes such as firefly and bacterial luciferases, Renilla luciferase, and 
aequorin. Different formats were also applied to improve the performance and 
portability of these analytical devices. Two main typologies may be identified: liquid-
phase biosensors featuring bioluminescent cells in suspension in a growth medium3 
or immobilized-phase biosensors in which cells are preserved in a hydrogel matrix.4,5 
Despite the high number of reported applications, few efforts were put on the 
improvement of the transducer element, i.e. the BL reporter protein. Most of 
developed whole-cell biosensors rely in fact on the P. pyralis luciferase which has a 
quantum efficiency close to 90%, does not require any post-translational modification 
for enzyme activity and it is not toxic even at high concentrations, being thus suitable 
for in vivo applications in prokaryotic and eukaryotic cells.6,7 Several commercially 
available luciferase activity assays have been developed permitting single-step 
reporter activity measurements, also including cell lysis. Alternatively, bacterial 
luciferase (lux) is unique in that it is the only bioreporter system available that 
generates its own substrate, thus eliminating the need for exogenous substrate 
addition. However, due to the low expression levels of bacterial luciferase in 
mammalian cells, to date few lux-based mammalian cell-based assays have been 
developed. New codon-optimized versions of the luxA and luxB genes from 
Photorhabdus luminescens were also produced to increase the expression levels in 
mammalian cells.8 Other BL proteins cloned from different organisms or obtained by 
random and site-directed mutagenesis are now being explored to expand the 
applicability and analytical performance of BL assays.9,10 These mutants are suitable 
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for improved dual-color reporter assays, biosensor measurements, and in vivo 
imaging techniques. Besides these mutants, also the cloning of new luciferases from 
different organisms, like those from L. italica and Cratomorphus distinctus, obtained 
will certainly improve current applications and make novel ones possible.11-15  Few 
works report the use of different luciferases to develop multiplexed assays, for 
example Nakajima et al. proposed a novel reporter assay system in which three 
luciferases that emit at different wavelengths (green, orange, and red) in the 
presence on the same substrate were used as reporter proteins. By measuring the 
emission of the three BL proteins with suitable optical filters and applying a signal 
process algorithm, the authors developed a monitoring system for the simultaneous 
evaluation of the expression of three different genes within a cell.16  Quite a few 
studies compared the performance of different reporter genes. Hakkila et al. 
investigated the suitability of firefly luciferase, bacterial luciferase (Photorhabdus 
luminescens luxCDABE), green fluorescent protein from Aequorea victoria, and red 
fluorescent protein (Discosoma sp. dsRed) in whole-cell bacterial sensors. The 
lowest detectable concentration of analytes and the fastest responses were achieved 
with firefly luciferase or luxCDABE as reporter genes.17 The use of secreted BL 
reporters has very seldom been reported. Recently Wu and coworkers reported a 
dual-assay with Gaussia and Cypridina luciferases as secreted reporters.18 Gaussia 
luciferase (Gluc) has several advantages over previous luciferases: (i) it possesses a 
natural secretory signal of 16 aminoacids that drives its secretion into cell medium, 
thus allowing BL measurements without cell lysis; (ii) it is the smallest luciferase 
cloned (19.9 kDa); (iii) its codon-humanized version produces a 100-fold higher 
luminescent signal intensity compared to firefly luciferase.19 Recently many works 
have been reported in which secreted reporter proteins are used to monitor protein 
secretory pathways in living mammalian cells, to detect protein-protein interactions, 
and to monitor bacterial cells in adverse conditions.
 20-22 
The BL measure of secreted 
reporter proteins is in fact easily performed in the cell culture supernatant, allowing 
repetitive measurements of the same cell sample by simply taking out small medium 
aliquots (eg., 10 µL). In the present study the suitability of using both intracellular and 
secreted BL proteins in a mammalian cell-based assay has been investigated. In 
particular the secreted Gaussia luciferase was used in combination with  two different 
couples of red- and green-emitting luciferases (red- and green-emitting thermostable 
versions of  P. pyralis luciferases and red- and green-emitting luciferases originally 
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cloned from the click beetle Pyrophorus plagiophthalamus). To evaluate Gaussia 
luciferase as a potential reporter to be used in combination with intracellular 
luciferases we preliminary transfected the firefly luciferases and Gaussia luciferase 
reporter vectors into mammalian cells and compared the levels of luciferase activity. 
Two vitality controls (an intracellular firefly luciferase and the secreted Gaussia 
luciferase) were introduced to first evaluate the suitability of secreted Gaussia 
luciferase as reporter protein by comparison to the more conventional intracellular 
luciferases. Since these luciferases need different substrates the signals were 
measured in separate wells of a 96-well microtiter plate by adding coelenterazine or 
luciferin. By combining intracellular and secreted luciferases it was in fact possible to 
simultaneously measure the activities of the two firefly luciferases by splitting their 
emission with optical filters and measure the Gaussia luciferase directly in cell 
medium aliquots.  
Matherials and methods 
Materials and plasmids. The Bright-GloTM luciferase assay system was from 
Promega. The plasmid pcDNA3-hGluc for expression of humanized Gaussia 
princeps luciferase and pUC19-Gluc were a kind gift of Dr. Bruce Bryan (NanoLight 
Technologies, Pinetop, AZ, USA). Ampicillin, isopropyl β-D-thiogalactopiranosyde 
(IPTG) and coelenterazine were obtained from Sigma (St. Louis, MO). Human 
hepatocarcinoma HepG2 cells were a generous gift from Prof. N. Carulli from the 
University of Modena, Italy. Materials used for culturing of cells were from Invitrogen. 
The plasmids pCBG99-Basic and pCBR-Basic were from Promega. The plasmid 
pCyp7a1-Ppy WT containing the portion of the human cyp7a1 promoter -1887/+24 
and Photinus pyralis luciferase wild-type (Ppy WT) as reporter gene was a generous 
gift of  Prof. John Y.L. Chiang (Northeastern Ohio Universities College of Medicine, 
Ohio, USA). The plasmids pGEXPpy GR-TS and pGEXPpy RE-TS expressing red- 
and green-emitting thermostable mutants of Photinus pyralis luciferase have already 
been described.23 The red- (CBRluc) and the green-emitting luciferase (CBG99luc)  
were inserted into pcDNA3.1 (+) vector backbone (Invitrogen) by mean of a blunt 
ligation. Obtained plasmids were named pcDNA 3.1-CBRluc and pcDNA 3.1-
CBG99luc. The CBG99luc was cloned into pCyp7a1-PpyWT to replace P. pyralis 
wild-type luciferase. The plasmid was named pCyp7a1-CBG99luc. All constructs 
were verified by restriction digestions and DNA sequencing. The bile acid 
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chenodeoxycholic acid (CDCA), as sodium salt, was purchased from Sigma–Aldrich. 
All the other reagents were of analytical grade or of the highest purity available. 
Bacterial dual reporter systems To investigate the best intracellular luciferase pair for 
cell-based reporter assays, dual-reporter model systems were first developed. The 
Ppy WT, PpyGR-TS, and PpyRE-TS were expressed in 5 mL Luria Bertani medium 
cultures of E. coli strain JM109 grown at 37°C overnight and diluted in 20 mL LB 
medium to midlog phase (A600nm 0.6). Then cultures were induced with 0.1 mM IPTG 
for 2 hours. The following luciferase pairs were used: Ppy WT and PpyRE-TS, PPy 
GR-TS and PpyRE-TS. Different proportions of cell cultures expressing the 
luciferases were transferred in a total volume of 100 µL in a 96-well microtiter plate. 
All combinations were tested in triplicate. A Luminoskan Ascent equipped with an 
injector for substrate addition was used for luminescence measurements. An amount 
of 100 µL of D-luciferin 1 mM in 0.1 M Na citrate buffer solution at pH 5.0 were 
injected with an automatic dispenser and after a brief shaking luminescence 
measurements were performed with 5 s integration. Luciferase activities were 
measured in the absence or presence of two emission filters (537 nm and 612 nm, 
band pass 20 nm). Light emissions were expressed as relative light units (RLU).  
Cell culture and mammalian triple reporter systems. Stable clones of HepG2 cells 
overexpressing the farnesoid X receptor (FXR)24 were transiently transfected or co-
transfected with the plasmids pCyp7a1-PpyWT, pcDNA3.1-Ppy RE-TS, and pcDNA3-
hGluc or with pCyp7a1-CBG99luc, pcDNA3.1-CBRluc, and  pcDNA3-hGluc. All 
experiments were run in triplicate and repeated at least four times. HepG2-FXR cells 
were grown routinely in 5% CO2 in air in MEM (minimum essential medium with 
Earle's salts) supplemented with 10% (v/v) fetal calf serum, 2 mM L-glutamine, 0.1 
mM non-essential amino acids, MEM vitamins and antibiotic/antimycotic solution. 
Stock solutions of CDCA (10−2 M) were prepared in absolute ethanol and diluted in 
cell culture medium. The final ethanol concentration added to the cells was 0.05% 
(v/v; the same ethanol concentration, as vehicle, was added to control cells). Briefly, 
104 cells were seeded in 24-well plates using the cation polymer transfection reagent 
ExGen 500 (MBI Fermentas, Vilnius, Lituania) following the manufacturer's 
specifications; in each assay, 0.5 μ/well of each plasmid were cotransfected. All 
transfections were performed in triplicate.  Three days after triple co-transfection and 
treatment (usually 20 hrs) of the cells with the analyte (CDCA or other bile acids), 10 
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µL of the medium were transferred in triplicate to a 96 well-microtiter plate for Gluc 
activity measurements, cells were washed twice with phosphate-buffered saline and 
lysed with 200 µL of 1% Triton® X-100 for 5 min at 25°C. After centrifugation, 100 µL 
of surnatant were transferred to the 96 well-plate. Each lysate was analyzed 
sequentially for the presence of the green-emitting luciferase (Ppy WT or CBG99luc) 
and red-emitting luciferase (Ppy RE-TS or CBRluc) by the addition of 100 µL 
luciferase assay system (Promega) and reading using the two emission filters 
described above to quantify the light emitted by each luciferase. The Promega 
Chroma-Luc “Calculator” was used to determine the contributions of red- and green-
emitting luciferases.25 Gluc activity was assayed by addition of 20 µL of 
coelenterazine 5µM in PBS and 5 sec acquisition to 10-µL aliquots of cell medium. 
Each green signal (Ppy WT or CBG99luc) was normalized using the red (Ppy RE-TS 
or CBRluc) or Gluc signal as an internal control. To analyze the time course of Gluc 
synthesis and secretion the cells were transfected with the plasmid pcDNA3-hGluc 
and after 40 hours aliquots of cell medium were analyzed in triplicate for Gluc activity 
as already described; after medium replacement BL measurements were taken at 
different time intervals for an overall period of time of 12 hours. 
Results and discussion 
Dual-color assays. To develop a simultaneous monitoring system, in which the BL 
signals of two intracellular luciferases are spectrally resolved and a third BL signal is 
measured in the cell medium by addition of a different substrate, we first chose the 
best intracellular luciferase pair that allowed a good signal separation. In theory to 
reduce spectral overlap the two emitters should have the narrowest bandwidths 
possible, well-separated emission maxima and similar specific activities. Among 
available luciferases we selected two thermostable mutants of P. pyralis  luciferase 
with red and green emission (Ppy RE-TS and Ppy GR-TS, respectively) and two 
commercially available red and green luciferases from P. plagiophalam (CBG99luc 
and CBRluc). The P. pyralis thermostable mutants were documented to be well 
suited for reporter applications, having well-separated emission spectra and similar 
steady-state kinetic constants.23 As an alternative, the CBG99luc and CBRluc, 
specifically tailored to be used in dual-reporter applications, seem to be the more 
appropriate candidate for a triple assay.  
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The suitability of the Ppy mutants was first evaluated in E. coli: the red-emitting Ppy 
RE-TS (maximum emission at pH 7.8 and 25°C 615 nm) was used in combination 
either with P. pyralis  luciferase wild-type (Ppy WT, maximum emission at pH 7.8 and 
25°C 557 nm) or with the green-emitting Ppy GR-TS (maximum emission at pH 7.8 
and 25°C 548 nm). Different amounts of E. coli cell cultures expressing the two 
luciferase pairs (Ppy RE-TS and Ppy GR-TS; Ppy RE-TS and Ppy WT) were mixed in 
the wells of a 96-well microtiter plate to investigate the spectral resolution using 
optical filters. A preliminary measurement of the filter correction factors was made by 
assaying each luciferase separately with no filters, with the green filter and with the 
red filter. These values provided the calibrations constants for the Promega Chroma-
Luc calculator, an Excel spreadsheet designed to calculate corrected luminescence 
values from samples containing red- and green-emitting proteins.25 The relative 
amount of each luciferase was quantitated by simultaneous measurements of the red 
and green emissions in each well. Figure 1.A shows BL emissions obtained by 
mixing populations of E. coli JM109 cells expressing Ppy RE-TS and Ppy WT grown 
at 37°C. Simultaneous measurements of green-and red-emitters were performed in 
intact E. coli cells in a high-throughput 96-well microplate format, demonstrating the 
feasibility of using Ppy WT and Ppy RE-TS as a BL reporter pair. Even though these 
luciferases have very different relative high specific activities (Ppy RE-TS activity is 
15% that of Ppy WT), the lower activity of the red emitter is most likely balanced by 
its higher thermostability (Ppy RE-TS half-life at 37 °C 8.80 hrs; Ppy WT half-life at 
37 °C 0.26 hrs).Next the feasibility of using Ppy RE-TS and Ppy GR-TS was 
evaluated by measuring the spectral resolution of varying percentages of E. coli cells 
expressing the two luciferases at 37 °C (Figure 1.B). Although these two mutants 
show similar specific activity and well-separated emission spectra (67-nm 
separation), their levels of expression differ significantly when the enzymes are 
expressed in bacterial cells at 37 °C and their BL emissions are measured in intact 
cell. This is presumably due to the higher level of expression of the mutant Ppy GR-
TS if compared to the red one. We concluded that this luciferase pair is not suitable 
for dual reporter assays and selected as luciferase pairs Ppy RE-TS/Ppy WT and 
CBG99luc/CBRluc for developing an cell-based assay with a third secreted reporter 
protein.  
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Figure 1. (A) BL emissions of  Ppy RE-TS (
___
■
___
) and Ppy WT (
___
▲
___
) expressed in E. coli JM109 
cells grown at 37°C. (B) BL emissions of  Ppy RE-TS (
___
■
___
) and Ppy GR-TS (
___
▲
___
) expressed in 
E. coli JM109 cells grown at 37°C. Mean values are plotted, with standard deviations indicated by 
error bars. RLU, relative light units.  
 
Gaussia luciferase measurements in transiently transfected HepG2 cells. Thereafter, 
we evaluated the expression of these reporter proteins in mammalian cells, with the 
final goal of using the two red-and green-emitting luciferases together with a secreted 
luciferase, Gaussia luciferase, as third reporter protein. Since this protein is secreted, 
its BL activity is measured directly into the culture medium after addition of the 
substrate coelenterazine. In order to study the time required for synthesis and 
secretion of Gluc, HepG2 cells were transfected with a plasmid for Gluc constitutive 
expression and, after changing the medium, the amount of expressed Gluc was 
evaluated by BL measurements in the cell medium over a period of  24 hours. The 
evaluation of the time required to reach a steady state intensity in the BL signal is 
important to identify the period of time, after medium replacement, required to obtain 
a stable BL signal. Figure 2 shows that the time required to get a BL signal 
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comparable to that obtained after 40 hours post-transfection (without changing 
growth medium) was approximately 6-8 hours.An analytical approach in order to 
explore the level of synthesis and secretion of Gluc was also undertaken by 
Knappskog et al., who tested the effect of different signal peptides on the expression 
and secretion of Gluc in transiently and stably transfected CHO cells.26Our data 
confirm results obtained by these authors who reported an increase in BL activity in  
the medium for an overall period of 40-48 hours, then the signal reaches its 
maximum intensity.We then proceeded with a proof-of-concept experiment, the 
green-emitting luciferases were expressed under the regulation of the cholesterol 7-α 
hydroxylase (cyp7a1) promoter. This promoter is negatively regulated by bile acids. 
Chenodeoxycholic acid (CDCA), a FXR ligand, is the more active one, being able to 
inhibit cy7a1 transcriptional basal activity with an IC50 of approximately 10 µM 
(concentration of CDCA required to inhibit 50% of reporter activity).27 
 
Figure 2. Time course of Gaussia luciferase BL signal obtained after cell medium replacement. 
HepG2 cells were transfected with the plasmid pcDNA3-hGluc. 40-hrs after transfection, the BL 
emission was evaluated in a 10µL-aliquot of the culture medium. After growth medium replacement, 
the BL signal was evaluated during a period of 12 hrs. 
 
In the first triple assay the plasmids cyp7a1 Ppy WT, pcDNA3.1-Ppy-RE-TS, and  
pcDNA3-hGluc were co-transfected into HepG2-FXR cells to compare the analytical 
performance of the Ppy-RE-TS and the Gluc as internal control reporters. Figures 3.A 
and 3.B report the concentration-dependent inhibition of cyp7a1 by CDCA in the 
concentration range 10-100 µM. According to previously published data, treatment of 
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HepG2-FXR cells with CDCA in concentrations of 100 µM repressed the cyp7a1 Ppy 
WT reporter activity by more than 50%.  
 
Figure 3. Effects of CDCA on cyp7a1 transcription. (A) Bioluminescent emission of Ppy WT (
__
▲
__
 ) 
under the regulation of cyp7a1 promoter and emission of the constitutively expressed Ppy RE-TS ( 
__
■
__
) in the presence of increasing concentrations of CDCA. (B) Emission of 
 
the constitutively 
expressed Gluc (
__
▼
__
 ) in the presence of increasing concentrations of CDCA. Values are the mean ± 
standard deviation of triplicate samples measured with the green and red filters. G luc BL activity was 
assayed in 10µL-aliquots of cell medium after addition of coelenterazine.   
 
As shown in Figure 4, corrected signals obtained by calculating the ratio of Ppy WT 
emission (cyp7a1 transcriptional activity) over Ppy RE-TS emission (internal control) 
or the ratio of Ppy WT emission over Gluc emission (internal control) displayed a 
similar behavior. Both the two luciferases used for internal correction allowed to 
perform a signal correction according to cell vitality. An IC50 of 10 µM for CDCA was 
obtained with both the reporters, thus confirming the suitability of these luciferases 
for multiplexed assays. These data confirm that secreted BL proteins may be used in 
combination with intracellular luciferases to increase the number of information 
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obtainable from a single cell. Then, we investigated the combination of CBRluc, 
CBG99luc, and Gluc with the same procedure. The green luciferase was used as 
specific reporter to study cyp7a1 promoter activity, whereas CBRluc and Gluc were 
both used to monitor cell vitality. Due to its low expression in HepG-FXR cells, BL 
measurements with the red filter caused a decrease in the CBRluc BL signal intensity 
that dropped almost to zero (0.011 ± 0.004 without filter). This abolished the ability to 
correct the signal in the presence of 100 µM CDCA (Figure 5.A and 5.B).  
 
Figure 4. Corrected dose-response curves for CDCA calculated as the ratio of Ppy WT over Ppy RE-
TS emissions (
__
■
__
,
  
left Y axis )  and ratio of Ppy WT over Gluc emissions (
 __
▲
__
 , right Y axis) 
against concentration of CDCA. Values are the mean ± standard deviation of triplicate samples 
measured with the green and red filters.  
 
Also the intensity of CBG99luc BL signal under the regulation of cyp7a1 promoter 
was very low when compared to Ppy WT (basal reporter activity without CDCA 0.254 
± 0.03 vs. 18.03 ± 1.68, respectively). This diversity is certainly due to different levels 
of expression in mammalian cells and relative specific activities of firefly and click 
beetle luciferases. A BL signal corresponding to 54 ± 4% of the BL intensity without 
CDCA was obtained using Gluc as reporter protein. The high expression of Gluc in 
mammalian cells, permits in fact to reach higher sensitivities if compared to CBRluc 
and CBG99luc.  In a similar approach,  a red thermostable mutant of Luciola italica 
has been used together with PpyWT and Gluc to study the transcriptional regulation 
of the two pathways of bile acid biosynthesis28 confirming the feasibility of associating 
firefly luciferases with Gluc to develop multiplexed assays 
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Figure 5. Effects of CDCA on cyp7a1 transcription. (A) Bioluminescent emission of CBG99 (
__
▲
__
 ) 
under the regulation of cyp7a1 promoter and emission of the constitutively expressed CBR (
__
■
__
 ) in 
the presence of increasing concentrations of CDCA. (B) Emission of the constitutively expressed Gluc 
(
__
▼
__
 ) in the presence of increasing concentrations of CDCA. Values are the mean ± standard 
deviation of triplicate samples measured with the green and red filters. Gluc BL activity was assayed in 
10µL-aliquots of cell medium after addition of coelenterazine.  
 
Conclusion 
We concluded that the use of Gaussia luciferase in combination with P. pyralis 
mutants emitting at different wavelengths allows the development of multiplexed-
assays with the peculiar advantage of complete absence of interference between the 
BL signals. In addition, both the secreted or the intracellular luciferases may be used 
as internal vitality controls, thus increasing the flexibility of the assay. The use of 
secreted reporter BL proteins has several advantages if compared to more 
commonly reported intracellular ones and we demonstrated that mammalian cell-
based assays employing both secreted and intracellular luciferases take advantage 
of the multicolor technology provided by spectral resolution (e.g. when using red- and 
green-emitting firefly luciferases) and of the straightforward measurement in cell 
medium allowed by secreted BL proteins. A careful choice of the BL reporters must 
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be preliminarily taken into consideration since high divergence in the BL reporter 
expression levels may account for difficulties in performing signal correction. The use 
of three or more reporter proteins could be extremely useful to develop whole-cell 
biosensors and cell-based assays with internal correction for multianalyte detection, 
particularly in environmental and food analysis, for example to simultaneously 
monitor the presence of different heavy metals or endocrine disruptor compounds.   
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Abstract 
The availability of new bioluminescent proteins, obtained by cDNA cloning and mutagenesis 
of wild-type genes, expanded the applicability of these reporters from the perspective of 
using more proteins emitting at different wavelength in the same cell-based assay. By 
spectrally resolving the light emitted by different reporter proteins it is in fact possible to 
simultaneously monitor multiple targets. A new luciferase isolated from L. italica has been 
recently cloned and thermostable red- and green-emitting mutants obtained by random and 
site-directed mutagenesis. Different combinations of luciferases were used in vitro as purified 
proteins, and expressed in bacterial and mammalian cells to test their suitability for multicolor 
assays. A mammalian triple-color reporter model system was then developed using a green-
emitting wild-type P. pyralis luciferase, a red thermostable mutant of L. italica luciferase and 
a secreted Gaussia princeps luciferase (GLuc) to monitor the two main pathways of bile acid 
biosynthesis. The two firefly luciferases were used to monitor cholesterol  7-α hydroxylase 
and sterol 27- hydroxylase, while secreted constitutively expressed GLuc was used as an 
internal vitality control. By treating the cells with chenodeoxycholic acid it was possible to 
obtain dose-dependent inhibitions of the two specific signals together with a constant 
production of GLuc, which allowed for a dynamic evaluation of the metabolic activity of the 
cells. This is the first triple-color mammalian reporter assay that combines secreted and non-
secreted luciferases requiring different substrates, thus avoiding reciprocal interference 
between different BL signals. This approach is suitable for high content analysis of gene 
transcription in living cells to shorten the time for screening assays, increasing throughput 
and cost-effectiveness. 
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Introduction 
 
Reporter gene technology, based upon the splicing of transcriptional control elements 
to a variety of reporter genes (e.g., green fluorescent protein, β-galactosidase, 
aequorin, luciferases), has been successfully used to monitor the cellular events 
associated with signal transduction and gene expression.1-2 The principal advantages 
of reporter gene-based assays are their high sensitivity, reliability, convenience, wide 
dynamic range, and adaptability to high throughput-screening. The choice of reporter 
gene, however, depends on the cell line used, the nature of the experiment, and the 
adaptability of the assay to the appropriate detection method (e.g., single cell imaging 
versus well- or plate-based detection). Together with fluorescent proteins, 
bioluminescent (BL) proteins are by far the most used reporter proteins for 
bioanalytical applications, including the investigation of protein-protein interactions, 
protein conformational changes, protein phosphorylation, second messengers 
expression and, in general, the study of gene expression and gene regulation.3-8 Since 
BL proteins can be detected down to attomole levels,9 they allow ultrasensitive 
detection of the target analytes. This also enables the analysis of small-volume 
samples, which leads to the development of miniaturized and high-throughput assays.  
Among BL proteins, luciferase from the North American firefly Photinus pyralis is by far 
the most employed BL reporter gene. The firefly luciferase (Luc) catalyzes the 
formation of luciferyl-adenylate (LH2-AMP) from luciferin (LH2) and ATP. LH2-AMP is 
converted through a multi-step oxidative process to excited-state oxyluciferin, the light-
emitting product.10-12 The production of light is very efficient, with a quantum efficiency 
close to 90%.13-14 
Luciferase does not require any post-translational modification for enzyme activity and 
it is not toxic even at high concentrations, being thus suitable for in vivo applications in 
prokaryotic and eukaryotic cells. Several commercially available luciferase assay 
formulations have been developed permitting single-step reporter activity 
measurements, also including cell lysis.  
The recent availability of new reporter genes with improved BL properties, together 
with technical improvements, prompted the development of multiplexed cell-based 
assays and multicolor in vivo imaging. New BL reporter genes were recently obtained 
using a random and site-directed mutagenesis approach15, 16 or by cloning new BL 
proteins, like luciferase from L. italica and Cratomorphus distinctus.17, 18 However, very 
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few works regarding multicolor reporter assay systems have previously been reported 
in literature.19, 20 The bottleneck consists in the spectral unmixing that, when using 
more than two luciferases requiring the same substrate, does not allow to completely 
separate the BL signals. In order to perform this kind of calculation, an elegant Java 
plug-in for ImageJ was also written to deconvolute images composed of signals 
obtained with different filters.21 
Self-illuminating quantum dot conjugates have been used as well with potential 
applications for multiplexing bioluminescence imaging and developing quantum dot-
based biosensors.22, 23 
Alternatively, secreted BL reporter proteins that do not require cell lysis or special 
equipment (e.g. filtered luminometers) may be used although their expression has a 
higher variability and expensive substrates are required.24   
We report here for the first time a triple-color mammalian assay which combines 
spectral unmixing of green- and red-emitting luciferases with a secreted luciferase 
requiring a different substrate, thus allowing to measure three separate targets with 
high sensitivity and rapidity.  
Two thermostable red and green-emitting mutants were obtained by site-directed and 
random mutagenesis of the cDNA encoding the luciferase from the Italian firefly 
Luciola italica. The suitability of these new luciferases as reporter proteins was first 
assessed in bacterial cells by producing dose-response curves for isopropyl β-D-
thiogalactopyranoside (IPTG), used as model analyte. Once evaluated that both the 
two mutants gave dose-response curves parallel to that obtained with wild-type P. 
pyralis luciferase, spectra obtained with purified luciferases were compared to those 
produced using bacterial cells expressing the two luciferases. In order to select three 
luciferases, two intracellular luciferases and a secreted one, to be used for developing 
a triple mammalian assay, the best couple of intracellular  luciferases was first chosen. 
Different combinations of P. pyralis and L. italica mutants were mixed in different 
amounts either using purified proteins or using E. coli expressing the BL proteins and 
spectral resolution was evaluated.  
Then, a triple-reporter assay was developed using the green-emitting wild-type P. 
pyralis luciferase, a red-emitting thermostable mutant of L. italica luciferase, and a 
humanized version of Gaussia princeps luciferase. This humanized form was 
specifically produced with humanized codon usage to optimize its expression in 
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mammalian cells, showing a 200-fold higher signal intensity than the humanized form 
of Renilla luciferase.25 
The assay was developed in a 96-well format to in vivo monitor the two pathways of 
bile acid biosynthesis in a new cell-based perspective for high content screening, thus 
enabling multiparametric analysis of bioluminescent (and/or fluorescent) indicators to 
define cellular responses to specific treatments.26 
Bile acid biosynthesis is in fact a key step of intracellular cholesterol homeostasis and, 
in turn, affects the rate of cholesterol synthesis in hepatocytes. The "classic" pathway 
of bile acid formation starts with a 7α-hydroxylation of cholesterol by cholesterol 7α-
hydroxylase (CYP7A1) in the liver. The "acidic" pathway starts with a hepatic or 
extrahepatic 27-hydroxylation by sterol 27-hydroxylase (CYP27A1). In humans, the 
activity of CYP27A1 is negatively regulated by bile acids, of which chenodeoxycholic 
(CDCA) is the more active one. An important mechanism of regulation of CYP7A1 
activity is believed to take place at the level of gene transcription because changes in 
enzyme activity were found to parallel those in mRNA levels, although a post-
transcriptional regulation seems to be important.27-29 The transcriptional regulation of 
these enzymes is usually studied by cell-based reporter gene assays in which a single 
assay provides information regarding only the regulation of one promoter.   
We report here the development of a recombinant HepG2 cell-based luciferase assay 
with an internal vitality control that enabled us to evaluate the ability of natural and 
synthetic bile acids and other compounds to activate or inhibit the two bile acid 
synthesis pathways. 
 
Materials and methods 
 
Materials. Materials used for culturing of cells were from Invitrogen. The Bright-GloTM 
luciferase assay system was from Promega. The plasmid pcDNA3-hGLuc for 
expression of humanized Gaussia princeps luciferase was a kind gift of Dr. Bruce 
Bryan (NanoLight Technologies, Pinetop, AZ, USA). Ampicillin, IPTG, 
chenodeoxycholic acid  (CDCA), phenylmethanesulphonylfluoride (PMSF), 
coelenterazine and imidazole were obtained from Sigma (St. Louis, MO). Human 
hepatocarcinoma HepG2 cells were a generous gift from Prof. N. Carulli from the 
University of Modena, Italy. The plasmids pGEXPpy WT and pGEXPpy GR-TS
19
 
expressing the P. pyralis WT luciferase and its mutant containing the following 
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mutations Thr214Ala/Ala215Leu/Val241ile/Gly246Ala/Phe250Ser were used as 
starting point to clone the Ppy WT and Ppy GR-TS into pQE30 backbone (Qiagen). 
The plasmid pGL3CYP7A1-Luc containing the portion of the human CYP7A1 
promoter -1887/+24 and Photinus pyralis luciferase wild-type as reporter gene was 
kindly provided by Prof. John Y.L. Chiang (Northeastern Ohio Universities College of 
Medicine, Ohio, USA). The plasmid pSOH4.3 containing a 4.3 kb portion f the human 
CYP27A1 promoter was a kind gift of Prof. Sebastiano Calandra (University of 
Modena, Italy). 
Construction of Plasmids and Mutagenesis. The following primers were used to 
amplify a fragment of 531 bp (-500/+31) of the human CYP27A1 promoter using the 
plasmid pSOH4.3 as template: ForCyp27-531 
TATGGTACCCCAGGGATCAGATGACTGG (KpnI) and the reverse primer 
RevCyp27 TCTAAGCTTACCTCAGCCTCGCGCAG (HindIII); restriction sites are 
shown underlined. The optimized conditions for the PCR were as follows: 1x Pfx 
buffer, 2x Enhancer solution, 1.5 mM MgSO4, 0.3 mM dNTPs, 0.15 µM Primer 
RevCyp27, 0.15 µM Primer Forcyp27-431 or ForCyp27-951, 1 µg of DNA template, 
and 2 units of Platinum Pfx DNA polymerase (GIBCO, Inc., Gaithersburg, MD). The 
final volume of the PCR mixtures was 50 µL, and they were carried out with a MJ 
Research PTC 100 thermal cycler (Perkin Elmer). The PCR reactions were carried 
out with an initial denaturation at 95°C for 5 min followed by 30 cycles of amplification 
(denaturation at 95°C for 1 min, annealing at 58°C for 1 min, and extension at 68°C 
for 45 sec, with a final extension at 68°C for 5 min). PCR products were purified by 
gel extraction using the QIAquick Gel extraction kit (Qiagen) and then inserted into 
pGL3-Control vector (Promega, Madison, WI) which had been previously digested 
with the restriction enzymes KpnI and HindIII to replace SV40 promoter and give the 
plasmid pGL3-CYP27A1-Luc. The plasmid was sequenced to confirm the 
introduction of the promoter and verify that no mutation was introduced during PCR 
amplification. The QuikChange Multi Site-Directed Mutagenesis kit (Stratagene, 
Heidelberg, Germany) was used to perform site-directed mutagenesis using the L. 
italica luciferase wild-type DNA sequence (Pubmed no. DQ138966) in the pGEX-6P-
2 vector as a template. Green- and red-light emitting thermostable (TS) L. italica 
mutants were made and the peroxisome targeting sequences were removed in order 
to abolish peroxisomal transport and improve their expression in mammalian cells.30 
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The green-emitting mutant (Lit GR-TS) contains the mutations V243I, G248A and 
F252S; whereas the red-emitting enzyme (Lit RE-TS) has the S286T change. Both 
luciferases contain the mutations G216A, T217L, S234A, K547G, M548G and 
E356K. The mutants were inserted into pQE30 (Qiagen) using BamHI and PstI 
restriction sites.Two paired primers, which included restriction endonuclease sites, 
were designed to amplify the Lit RE-TS mutant cDNA: Primer HindIIILitRETSFor: 5‟-
GCAAGCTTATGGAAACGGAAAGGGAGGA- 3‟ (forward primer containing a HindIII 
site, underlined) and Primer XbaILitRETSrev: 5‟-
ATCTAGATTACCCCCCGGCTTGTGGTTTCT- 3‟(reverse primer containing a XbaI 
site, underlined). The PCR product was then cloned into pGL3-CYP27A1-Luc to 
replace wild-type luciferase of P. pyralis and give the plasmid pGL3-CYP27A1-LitRE-
TS. Lit RE-TS and Lit GR-TS mutants were also inserted into pcDNA3.1 (+) vector 
backbone (Invitrogen) and pGL3 vectors by mean of a blunt ligation. Obtained 
plasmids were named pcDNA 3.1-LitGR-TS and pcDNA 3.1-LitRE-TS, pGL3-LitGR-
TS and pGL3-LitRE-TS. All constructs were verified by DNA sequencing. 
Protein espression in E. coli and purification. Lit GR-TS and Lit RE-TS 6his-fusion 
proteins were first grown in E. coli strain BL-21 in 5-mL LB medium with 100 µg/ml 
ampicillin at 37°C overnight. These cultures were used to inoculate 250 ml cultures at 
a 1:100 dilution (LB-broth supplemented with 100 µg/ml ampicillin) and grown at 
37°C with shaking until an OD600nm of 0.6 was reached. Cultures were transferred to 
a 22°C incubator, allowed to equilibrate and induced with 0.1 mM IPTG overnight. 
Qiagen Ni-NTA resins were used for protein purification according to manufacturer's 
instructions with slight modifications. Briefly the cells were harvested by 
centrifugation, resuspended in 2 ml of lysis buffer (50mM NaH2PO4, 300mM NaCl, 10 
mM imidazole, 1 mM PMSF, pH 7) and sonicated using ten 10s bursts with a 15s 
cooling period on ice between each burst. The lysate was then centrifuged at 5000 
rpm for 1h at 4°C to pellet cellular debris and the supernatant was saved to proceed 
with protocol for purification under native condition. The cleared lysate was mixed 
with 1 mL of the 50% Ni-NTA slurry, loaded into a polypropylene columns (Qiagen) 
and washed twice with 4 mL wash buffer (50 mM NaH2PO4, 300mM NaCl, 20mM 
imidazole, 1mM PMSF, pH 7). 500-µL aliquots were eluted in Elution Buffer (50mM 
NaH2PO4, 300mM NaCl, 250mM imidazole, pH 7). Protein concentration was 
determined by Bio-Rad Microassay procedure using bovine serum albumin (BSA) as 
standard. The activity of the purified proteins was evaluated using a luminometer 
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(Luminoskan Ascent, Labsystem) using 4 µL of eluted protein, 100 µL phosphate 
buffered saline (PBS) and 100 µL of Bright-Glo™ Luciferase Assay System 
(Promega).  
Measurement of bioluminescence emission spectra. Emission spectra were obtained 
using an Eclipse spectrofluorometer (Varian) in „Bio/Chemiluminescence‟ mode 
(excitation source turned off). Reaction mixtures containing purified Lit RE-TS and Lit 
GR-TS (5-100 µg) in Elution Buffer, 70 µM D-luciferin (Synchem), and 2 mM Mg-ATP 
were brought to a final volume of 1 mL with 25 mM glycylglycine buffer (pH 7.8). 
Approximately 1 min after initiation of bioluminescence, spectra were recorded in a 
1.0 mL fluorescence cuvette and emission slit of 10 nm. Bandwidths of emission 
spectra were measured at 50 and 20% of the intensity at the maximum wavelength to 
investigate luciferase emission behavior and possible spectra broadening due to pH 
variations or altered cultural conditions. Spectra were also recorded using aliquots of 
E. coli cells expressing the two thermostable luciferases. Briefly, shake flasks (250 
ml) containing 20 ml of LB-broth and 100 µg/ml ampicillin were inoculated at a 1:50 
dilution using overnight cultures of E. coli JM109 harboring pQE30Lit RE-TS or 
pQE30Lit GR-TS. Cells were grown at 37°C to A600 ~0.4, supplemented with 0.1 mM 
IPTG to induce luciferase expression and incubated for 2 h at 22°C. Samples (1 mL-
aliquots ) were collected and the A600 was adjusted to 0.9 using LB. Aliquots (1 mL) 
were transferred to a fluorescence cuvette and 200 µL of 0.5 mM D-luciferin were 
added. After 5-min incubation at room temperature, bioluminescent emission spectra 
were collected as previously described. The pH of the mixtures was verified after 
each emission spectrum was measured.  
 Bacterial expression and model reporter system. To test the feasibility of using Lit 
RE-TS, and Lit GR-TS as reporter proteins, dose-response curves were produced in 
E. coli for IPTG, used as model analyte, and compared to those obtained with P. 
pyralis wild type luciferase (Ppy WT). Briefly, 90 µL aliquots of freshly grown bacteria 
in LB broth were transferred to a white 96-well microplate and mixed with IPTG 
standard solutions (to reach a final concentration of  1.0x10-6-1.0x10-1 mM. Bacteria 
were incubated at 30°C for 2 h. Luminescence measurements were taken with 5 sec 
acquisition. Then, dual-reporter model systems were developed to investigate the 
best luciferase pair for dual reporter assays. The Ppy WT, Ppy GR-TS, Lit RE-TS, 
and Lit GR-TS were expressed in 5 mL LB medium cultures of E. coli strain JM109 
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grown at 37°C overnight and diluted in 20 mL LB medium to midlog phase (A600nm 
0.6). Then cultures were induced with 0.1 mM IPTG for 2 hours. The following 
luciferase pairs were used: Ppy WT and Lit RE-TS, PPy GR-TS and Lit RE-TS, Lit 
GR-TS and Lit RE-TS. Different proportions of cell cultures expressing the luciferases 
were transferred in a total volume of 100 µL in a 96-well microtiter plate. All 
combinations were tested in triplicate. Luminescence measurements were performed 
with a  Luminoskan Ascent equipped with an injector for substrate addition. An 
amount of 100 µL of D-luciferin 1 mM in 0.1 M Na citrate buffer solution at pH 5.0 
were injected with an automatic dispenser and after a brief shaking luminescence 
measurements were performed with 5 s integration. Luciferase activities were 
measured in the absence or presence of two emission filters (537 nm and 612 nm, 
band pass 20 nm). Light emissions were expressed as relative light units (RLU). The 
Promega Chroma-Luc “Calculator” was used to determine the contributions of red- 
and green-emitting luciferases.31 
Cell culture. HepG2 cells were grown routinely in 5% CO2 in air in MEM (minimum 
essential medium with Earle's salts) supplemented with 10% (v/v) fetal calf serum, 2 
mM L-glutamine, 0.1 mM non-essential amino acids, MEM vitamins and 
antibiotic/antimycotic solution. Cells were stably transfected with pcDNA3.1-FXR 
expression vector containing the cDNA encoding human Farnesoid X Receptor 
(FXR), in order to obtain clones that stably over-expressed the receptor. Transfection 
was performed with calcium phosphate method and after 72 hrs selection of positive 
clones was obtained by addition of G418 to transfected cells to isolate clones stably 
expressing FXR receptor. Cell cultures were split 1:3 when reaching confluency.  
Correlation between Gaussia luciferase bioluminescence and cell number 
Approximately 1.5 x 105 HepG2 cells per well were transiently transfected with 0.5 µg 
of pcDNA3-hGLuc in a 24-well culture plate. Various concentrations of G418 (0, 100, 
200, 300, 400, 500, 600, 700 µg/mL) were administrated to cells and incubated for 48 
h. Viable cells were then counted by trypan blue exclusion. Linear regression 
analysis was performed between BL emission measured in 10 µL cell medium 
aliquots (by addition of 20 µL of coelenterazine 5µM in PBS and 5 sec acquisition) 
and viable cell count. All transfections were performed in  triplicate.  
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Dual and triple luciferase mammalian assays. Approximately 1.5 x 105 HepG2-FXR 
cells were seeded per well in 24-well cell culture plates one day before transient 
transfection. Cells were washed with PBS, then transiently transfected or co-
transfected with 0.5 µg of pGL3-CYP7A1-Luc and pcDNA 3.1-Lit RE-TS (or pGL3-Lit 
RE-TS) per well using Exgen500 (MBI Fermentas, Vilnius, Lithuania) according to the 
manufacturer's instructions. Alternatively cells were co-transfected with pGL3-
CYP7A1-Luc, pGL3-CYP27A1531Lit RE-TS and pcDNA3-hGLuc. Several parameters 
were optimized in order to increase the analytical performance of the bioassay, 
including cell number, incubation time with the analyte and transfection parameters. 
Each assay was performed in triplicate, and individual experiments were repeated at 
least 3 times. Three days after dual or triple co-transfection and treatment (usually 20 
hrs) of the cells with the analyte, 10 µL of the medium were transferred in triplicate to 
a 96 well-microtiter plate for GLuc activity measurements, cells were washed in PBS 
and lysed with 200 µL of 1% Triton® X-100 for 5 min at 25°C. After centrifugation, 
100 µL of surnatant were transferred to the 96 well-plate. Each lysate was analysed 
sequentially for the presence of the green-emitting luciferase (Ppy WT) and red-
emitting luciferase (Lit RE-TS) by the addition of 100 µL luciferase assay system 
(Promega) and reading using the two emission filters described above to quantify the 
light emitted by each luciferase. The Promega Chroma-Luc “Calculator” was used to 
determine the contributions of red- and green-emitting luciferases.31GLuc activity was 
assayed by addition of 20 µL of coelenterazine 5µM in PBS and 5 sec acquisition. 
Each red (Lit RE-TS) or green (Ppy WT) signal was normalized using the GLuc signal 
as an internal control.  
 
RESULTS AND DISCUSSION 
Overexpression, purification, and bioluminescent emission of luciferase proteins. 
Red- and green-emitting thermostable mutants of L. italica luciferase were obtained 
by random and site-directed mutagenesis. The two luciferases Lit GR-TS (G216A, 
T217L, S234A, V243I, G248A, and F252S) and Lit RE-TS (G216A, T217L, S234A, 
and S286T) were purified to homogeneity in yields of 4-10 mg/L. Normalized 
bioluminescence spectra, shown in Figure 1, were obtained at pH 7.8 as described in 
the Materials and Methods section. The relative (to PpyWT) flash height specific 
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activities of LitRE-TS and Lit GR-TS were 42% and 67%, respectively. Lit GR-TS 
showed a broader emission spectrum with a maximal emission wavelength at 550 
nm, whereas the mutant Lit RE-TS showed a maximum emission at 613 nm with a 
sharper spectrum (Table 1). Dose-response curves for IPTG were also produced to 
investigate the feasibility of using the two mutants of L. italica luciferase as reporter 
proteins in bacterial whole-cell biosensors or other bioanalytical applications. Dose-
response curves, obtained in the range 1.0x10-6-1.0x10-1 mM, were compared to 
those produced using the wild-type luciferase of P. pyralis as reporter protein. As 
shown in Figure 2, for both the two mutants the light emission was proportional to the 
amount of added IPTG over four to five orders of magnitude. The limits of detection 
for IPTG (blank plus three times the standard deviation) were (1.0 ± 0.2) x 10-6 mM 
with Lit RE-TS,  (5.0 ± 0.3) x10-6 mM with Ppy WT, and (1.0 ± 0.2) x 10-5 mM with Lit 
GR-TS as reporter protein, demonstrating the feasibility of using these luciferase 
mutants as BL bioreporters in bacterial cells. Bioluminescence spectra were then 
collected using E. coli cells expressing Ppy WT, Ppy GR-TS, Lit GR-TS, and Lit RE-
TS to compare emission obtained with purified proteins and emission obtained within 
recombinant cells. Figure 3 shows bioluminescent spectra obtained using 
recombinant bacterial cultures. The previously reported mutant Ppy GR-TS was 
selected for its excellent thermostability (37°C half-life = 10.5 h) and for its emission 
properties: an emission maximum of 548 nm at pH 7.8 and 25°C with a bandwidth 
similar to Ppy WT and a relative (to PpyWT) specific activity of 58%.19 These 
desirable characteristics, together with its good specific activity and substrate Km 
values similar to Ppy WT, make this mutant the best green-emitting candidate for 
dual-color reporter systems.The pH of the mixtures, measured after each emission 
spectrum was collected, ranged from 6.2 to 6.4. Since firefly luciferases are pH 
sensitive and may change emission wavelength at different pH, the pH was 
measured to investigate if an eventual red shifting or spectrum broadening caused by 
pH lowering could interfere with the signal separation. At the measured pH, emission 
maxima were 560 nm for Ppy WT, 551 nm for Ppy GR-TS, 565 nm for Lit GR-TS, 
and 613 nm for Lit RE-TS. Actually, the intracellular pH could be higher than the pH 
of cell mixtures, thus explaining the absence of a marked red-shifting in the emission 
of Ppy WT. The bioluminescent spectrum recorded for Lit GR-TS expressed in E. coli 
showed a markedly red-shifted emission spectrum which overlapped with the 
emission of Lit RE-TS . Table 1 shows that Lit GR-TS has also a broader emission 
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curve when compared to the other three luciferases (e.g., Lit GR-TS has a 50%  
emission bandwidth of 92 nm vs Ppy WT 50% emission bandwidth of 66 nm). 
Therefore this mutant was excluded to further investigations for  in vivo dual-reporter 
applications. In contrast, Ppy WT and Ppy GR-TS provided a separation from Lit RE-
TS of 53 nm and 62 nm when expressed in E. coli cells, respectively.  
 
Figure 1: Normalized BL emission spectra of  Lit GR-TS (dotted line) and Lit RE-TS (straight line) 
obtained at pH 7.8. Conditions for recording the emission spectra are described under Materials and 
Methods section. 
 
Enzyme In vitro (pH 7.8) 
Maxima (nm)               
Bandwidth 
                                   50%         
20% 
In vivo (pH 6.3) 
Maxima (nm)              
Bandwidth 
                                   50%         
20% 
Ppy WT 557* 68* 113* 560 66 108 
Ppy GR-TS 546* 66* 110* 551 68 106 
Lit GR-TS 550 79 130 565 92 127 
Lit RE-TS 613 66 114 613 52 88 
 
* See Branchini et al., 2007.19 
Table 1 Bioluminescent emissions of the purified luciferases (in vitro) and of E. coli cells expressing 
the luciferases (in vivo). 
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Figure 2: Dose response curves for IPTG obtained using JM109 cells harbouring plasmid with Lac 
promoter driving the expression of Lit RE-TS (Fig. 2. A 
__
■
__
), Ppy WT (Fig 2. A - - -▼- - -) or Lit GR-
TS (Fig. 2. B. 
__
▲
__
).  
 
Figure 3: Normalized BL emission spectra obtained after addition of 100 μL of 1 mM D-luciferin in 0.1 
M Na-citrate-buffer at pH 5 to 100 µL JM109 E.coli cells expressing Ppy WT (grey line), Ppy GR-TS 
(dotted line), Lit GR-TS (dashed line), and Lit RE-TS (straight line) in pQE30 vector.  
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Model dual-color assays. After checking that emission spectra obtained using 
bacterial cells expressing luciferase mutants mirrored those obtained with purified 
proteins, preliminary experiments were performed to investigate the best luciferase 
pair to be used in whole-cell dual-reporter applications. Ideally, in a dual-color system 
the emission spectra of the two reporters would not overlap. Unfortunately two BL 
proteins requiring the same substrate whose emissions do not overlap at all have not 
been identified yet. To minimize spectral overlap, the two emitters should have the 
narrowest bandwidths possible and well separated emission maxima. According to 
BL emission spectra, Ppy GR-TS and Ppy WT seem to be the more suitable green-
emitting candidates for dual-color assays. The red-emitting Lit RE-TS was used in 
combination with the two green-emitting luciferases, Ppy WT and PPy GR-TS, to 
quantitate the relative amount of each luciferase by simultaneous measurements of 
red and green emission. Different amounts of cell cultures expressing the two 
luciferases were mixed to investigate the spectral resolution using the filter pair 
already described. A preliminary measurement of the filter correction factors was 
made by assaying each luciferase separately with no filters, with the green filter and 
with the red filter. These values provided the calibrations constants for the Promega 
Chroma-Luc calculator, an Excel spreadsheet designed to calculate corrected 
luminescence values from samples containing red- and green-emitting proteins. As 
previously reported, the concept of detection limit in a dual-color assays is not easy 
to define.15 In fact, the luminescent  signal from one emitter (eg., green) transmitted 
through the filter used to monitor the other emitter (eg., red), i.e. the interference, 
must be taken into consideration together with the background noise when 
calculating the detection limit. This interference is concentration-dependent, meaning 
that the detection limits and the working range of an emitter are dependent on the 
concentration of the other. Figure 4 shows BL emissions obtained mixing populations 
of E. coli JM109 cells expressing Lit RE-TS and Ppy WT grown at 37°C. 
Simultaneous measurements of green-and red-emitters were performed in intact E. 
coli cells in a high-throughput 96-well microplate format, demonstrating the feasibility 
of using Ppy WT and Lit RE-TS as a BL reporter pair. The deviation at low % of Lit 
RE-TS is due to the detection limit issues that arise from the overlap of the long 
wavelength “tail” of the non-Gaussian Ppy green enzyme spectrum. Because the 
overall activity of the green enzyme is higher than the red, the contribution of the 
overlapping signal is more significant at low percentages of the red emitter. The 
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importance of using two luciferases with similar expression levels in the system is 
well explained using Lit RE-TS and Ppy GR-TS as luciferase pair. Although these 
luciferases provide the best separation (62 nm), their expression levels in E. coli are 
very different and the very high BL intensity of Ppy GR-TS did not allow an accurate 
quantitation of  low amounts Lit RE-TS (data not shown).  In addition we 
demonstrated that these luciferases could be adapted for use with a single 
commercial reagent in a standard microplate luminometer protocol without the need 
to lyse cells, differently form previous works19 in which the feasibility of using two red-
and green Ppy mutants in dual-analyte assays was investigated using E. coli lysates 
from cells grown at 37°C. From these preliminary data, we concluded that Ppy WT 
and Lit RE-TS are the best luciferase pair for dual-color assay. In fact, these proteins 
have good spectral separation and similar expression levels, requiring the same 
synthetic substrate, D-luciferin.  In other experiments, either the amount of red- or 
green-emitting luciferase was held constant while the amount of the other was varied 
(data not shown) and obtained data confirmed results previously shown. 
 
Figure 4. BL emissions of  Lit RE-TS (■) and Ppy WT (▲) expressed in E. coli JM109 cells grown at 
37°C. Mean values are plotted, with standard deviations indicated by error bars. RLU, relative light 
units.  
 
Correlation between Gaussia luciferase bioluminescence and viable cell number. To 
preliminary evaluate the possibility to use GLuc as reporter gene in mammalian cell-
based assays, the correlation between BL emission and cell viability was 
investigated. 
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Figure 5 shows the results of BL measurements in cell medium aliquots and viable 
cell counts using the trypan blue-exclusion method after treatment with different 
concentrations of G418 (range 0-700 µg/mL), an antibiotic used to select and 
maintain stable eukaryotic cell lines. As the numbers of HepG2 cells decreased, the 
bioluminescence decreased as well (r2 = 0.9992), demonstrating the feasibility of 
using GLuc as internal control to monitor cell vitality. 
 
Figure 5: Correlation of BL emission in cell medium with viable cell number in the presence of 
increasing concentrations of G418. HepG2 cells were transfected with pcDNAhGluc and treated with 
G418 according to Materials and Methods section. Cell viability was determined by trypan blue 
exclusion. Linear regression analysis indicated high correlation between cell number and 
bioluminescence (r
2
 = 0.9992). 
 
Dual and triple reporter assays in mammalian cells. Next, we extended the promising 
results obtained with the bacterial dual-reporter model system based on E. coli cells 
expressing Ppy WT and Lit RE-TS to a mammalian model system. To investigate the 
feasibility of this system, reporter plasmids harbouring these luciferases were 
constructed with the final goal of studying the transcriptional regulation of  CYP7A1 
and CYP27A1, the two main enzymes responsible for bile acid biosynthesis in 
humans. Since no cell-based assays have been reported to simultaneously monitor 
the transcriptional regulation of these two enzymes, a reliable and accurate bioassay 
that allows a rapid and high throughput analysis of compounds able to regulate these 
two pathways would certainly be of great value. First, the Lit RE-TS was used as 
internal vitality control under the regulation of SV40 promoter, selected for strong 
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constitutive expression of the reporter protein, in pGL3 backbone. The plasmid pGL3-
Lit RE-TS was transiently co-transfected with the plasmid pGL3CYP7A1-Luc in 
HepG2-FXR cells. 48-Hours after co-transfection, cells were treated with CDCA, a 
FXR ligand, in the concentration range 10-100 µM. According to previously reported 
data, a concentration-dependent inhibition of CYP7A1 by CDCA is shown in Figure 
6A. Treatment of HepG2-FXR cells with CDCA in concentrations of 100 µM 
repressed the pGL3CYP7A1-Luc reporter activity by more than 50%. Due to CDCA 
toxicity at concentrations higher than 50 µM, an internal correction is mandatory to 
take into account changes in cell vitality. The introduction of an internal control 
allowed to correct the response of the Ppy WT using the ratio of Ppy WT emission 
over Lit RE-TS emission (Fig. 6B). By comparing the BL emissions of Ppy WT and 
LitRE-TS in the presence of increasing concentrations of CDCA it is evident that the 
reduced emission of Ppy WT can be partly attributed to the reduction in cell viability 
(e.g., 36% loss in viability as compared with 81% loss in Ppy WT specific emission 
for samples containing 100 µM CDCA). The reduction in cell metabolism is a 
consequence of exposing the cells to sublethal concentrations of the toxicants. In 
fact, hydrophobic bile acids like CDCA solubilize membrane-bound lipids, leading to 
damage to cell membranes.32 The altered overall metabolism may in turn affect 
protein expression in the cell, including reporter proteins. The concentration of CDCA 
required to inhibit 50% of reporter activity (IC50) was determined to be
 approximately 
10 µM. Similar result were obtained co-transfecting HepG2 cells, an IC50 of 30 µM 
and 25 µM were determined by transfecting cells with pcDNA 3.1-Lit RE-TS or pGL3-
Lit RE-TS, respectively (data not shown). The two plasmids were selected to 
compare the mammalian expression of Lit RE-TS under the regulation of two 
different constitutive promoters: the CMV promoter in pCDNA 3.1 backbone and HSV 
promoter in pGL3 backbone. These values are consistent with previous published 
results reported by Chiang et al., who studied the effect of CDCA on CYP7A1 
transcription in HepG2 cells cotransfected with a CYP7A1/luciferase reporter and an 
FXR expression plasmid, obtaining an IC50 of 25 µM without FXR and 10 µM with 
FXR.33Assay reproducibility was evaluated at a fixed concentration of CDCA (10 µM); 
an intra-assay variability of  8.9 % and an inter-assay variability of 15.4 % (n=6) were 
obtained. A triple assay was then developed using three BL reporters: Ppy WT, Lit 
RE-TS and Gaussia princeps luciferase. The introduction of a third reporter protein, 
GLuc, whose activity can be measured directly in the medium with a different 
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substrate (coelenterazine), gives the remarkable advantage of a “separate” internal 
correction. That means that the two luciferases (Ppy WT, Lit RE-TS) can be used for 
measuring two analytes, and cell vitality is measured by simply taking out an aliquot 
(10 µL) of the medium and measuring it in the same 96 well-microplate used for the 
bioassay.  
 
Figure 6. Effects of CDCA on CYP7A1 transcription. 6.A. Bioluminescent emission of Ppy WT (
__
■
__
) 
under the regulation of CYP7A1 promoter and emission of the constitutively expressed Lit RE-TS (- - -
▲- - -) in the presence of increasing concentrations of chenodeoxycholic acid. Values are the mean ± 
standard deviations of triplicate samples measured with the green and red filters in place. 6.B. 
Corrected dose-response curve for CDCA (ratio of Ppy WT emission over Lit RE-TS emission against 
[CDCA],  
__
▼
__
). Data are the average ± one standard deviation.  
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Figure 7 shows the non-corrected BL emissions of the two reporters (Fig.7A) and the 
BL emission of the vitality control GLuc (Fig 7B) in the presence of increasing 
concentrations of CDCA. By using the ratio of Ppy WT or Lit RE-TS emission over 
GLuc emission it was possible to correct both the two specific signals according to 
cell vitality and cell number in each well. As expected, addition of 50 µM of CDCA 
inhibited 73% of CYP7A1/Ppy WT and 62% CYP27A1/Lit RE-TS reporter activities, 
considering a 17 % aspecific loss in cell viability, as determined with GLuc BL activity 
in the medium (Figure 8). The response was reproducible at fixed concentrations of 
CDCA (10 µM), with an intra-assay variability of 15.0 % and 18.3 %  and an inter-
assay variability of 18.1% and 21.8%  (n=6)  for CYP7A1 and CYP27A1, 
respectively. Since the signal correction is the major concern of bioassays and 
whole-cell biosensor applications, a cell vitality control that does not interfere with 
specific signals, as proposed in the present work, will certainly improve the analytical 
performance of these assays. Current protocols are mostly based on the dual 
luciferase reporter assay system (Promega) involving the use of a firefly luciferase for 
monitoring gene expression and a Renilla luciferase as internal control. 
Unfortunately, this system is laborious and requires expensive reagents. Secreted 
proteins could be a valid alternative to normalize reporter data in a single, facile step. 
The applicability of secreted proteins has very recently pointed out by Wu et al.,24 
that reported a dual-reporter assay using Cypridina and Gaussia luciferases; both 
these luciferases are secreted into the medium via the endoplasmic reticulum and 
the Golgi complex. The major advantages of using secreted proteins reside in the 
rapidity of the assay (no need for cell lysis), absence of interference with 
measurements of intracellular reporter proteins, and in the possibility to conduct 
repetitive studies on the same cell population by simply taking out small aliquots 
(e.g., 10 µL) of cell medium. Furthermore, this has the great advantage of complete 
absence of interference between intracellular and secreted bioluminescent emission: 
the two signals are in fact measured in separate wells of a high throughput 96-well 
microtiter plate. By employing secreted reporters it is therefore possible to implement 
BL cell-based assays and increase their analytical performance by taking advantage 
of both multicolour reporter gene technology and the ease of use of secreted 
proteins.  
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Figure 7: Effects of CDCA on CYP7A1 and CYP27A1 transcriptions. 7.A. BL emission of Ppy WT 
(
__
■
__
) under the regulation of CYP7A1 promoter and BL emission of Lit RE-TS (- - -▲- - -) under the 
regulation of CYP27A1 promoter in the presence of increasing concentrations of chenodeoxycholic 
acid.  Values are the mean ± standard deviations of triplicate samples measured with the green and 
red filters in place. 7. B. BL emission of constitutively expressed Gaussia luciferase (
__
▼
__
) used as 
internal control.  
 
 
 
Figure 8: Corrected dose-response curves for CDCA on CYP7A1 (
__
■
__
) and CYP27A1 (
__
▼
__
) 
transcriptions (ratio of Ppy WT/Lit RE-TS emission over GLuc emission against [CDCA]).  
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CONCLUSIONS 
A triple-reporter cell-based BL assay was developed in a high throughput 96-well 
microtiter plate format combining two different intracellular firefly luciferases as 
reporters and a secreted luciferase as internal control. Green- (P. pyralis wild type 
luciferase) and red-emitting (a thermostable mutant of L. italica luciferase) BL 
proteins were put under the regulation of CYP7A1 and CYP27A1 promoters, 
respectively, in order to monitor the two main bile acid biosynthesis pathways. In 
addition the secreted Gaussia luciferase, which employed a different BL substrate, 
was used as vitality control under the regulation of a constitutive promoter. The use 
of a secreted BL reporter simplified the measure of its activity because it can be 
separately evaluated on small aliquots of cell-culture medium. The developed assay 
does not suffer the limitations of previous triple-reporter assays based on green-, 
orange-, and red-emitting clickbeetle luciferases, such as errors in deconvolution 
process due to overlapping emissions. Therefore, this triple-reporter assay, the first 
reported in literature employing both intracellular and secreted luciferases, paves the 
way for the monitoring of multiple metabolic events for high-content screening.    
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General Discussion 
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General Discussion 
The mechanism of color tuning in bioluminescent reactions is not fully understood yet 
but it is object of intense research and several hypothesis have been generated. In 
the past decade key residues of the active site of the enzyme or in the surface 
surrounding the active site have been identified as responsible of different color 
emission. Anyway since bioluminescence reaction is stricty dependent from the 
interaction between the enzyme and its substrate D-luciferin, modification of the 
substrate can lead to a different emission spectrum too.In the recent years firefly 
luciferase and other luciferases underwent mutagenesis in order to obtain mutants 
with different emission characteristics. Thanks to these new discoveries in the 
bioluminescence field multicolor luciferases can be nowadays employed in 
bioanalysis for assay developments and imaging purposes. The use of multicolor 
bioluminescent enzymes expanded the potential of a range of application in vitro and 
in vivo. Multiple information can be obtained from the same analytical session saving 
cost and time. This thesis focuses on several application of multicolor 
bioluminescence for high-throughput screening and in vivo imaging. Multicolor 
luciferases can be employed as new tools for drug discovery and developments and 
some examples are provided in the different chapters. New red codon optimized 
luciferase have been demonstrated to be improved tools for bioluminescence 
imaging in small animal and the possibility to combine red and green luciferases for 
BLI has been achieved even if some aspects of the methodology remain challenging 
and need further improvement. Other potentialities of multicolor bioluminescence in 
imaging can arise from the application of RET (resonance energy transfer) and Split 
luciferase technologies involving protein complementation assays (PCA). In the first 
case luciferase mutants with an emission peak at an opportune wavelengths can be 
better donor in energy transfer process to acceptor counterparts and lead to emission 
in the far red or infrared region of the UV/Visible spectrum. An example of this is 
reported by the use of PpYRE8 as donor for the development of an near-infrared 
probe relying on the conjugation of luciferase with a fluorescent dye (e.g. AF680) for 
an efficient intramolecular energy transfer. In the second case luciferase enzyme can 
be splitted in two inactive polypeptides (split reporter fragments) that will recover 
activity only when they reconstitute. For instance, Hida and collegues and  developed 
a novel luciferase fragment by random mutagenesis and realized cross 
complementation between inter- and intra-luciferase fragments with high efficiency 
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They showed potential applications of the luciferase fragments for real-time and dual 
imaging in live Xenopus laevis embryo. In addition, Villalobos et al. described a set of 
reversible multicolored heteroprotein complementation fragments based on various 
firefly and click beetle luciferases that utilize the same substrate, D-luciferin. 
Luciferase heteroprotein fragment complementation systems enabled dual-color 
quantification of two discrete pairs of interacting proteins simultaneously or two 
distinct proteins interacting with a third shared protein in live cells. In analogy, the 
multicolor optimized luciferases described in this thesis might be used for developing 
new more sensitive imaging tools for in vivo analisys of protein protein interaction 
essential for understanding molecular pathways . At the same time the development 
of more sensitive and implemented microscopes and low-light imager for a better 
visualization and quantitation of multicolor signals would boost the research and the 
discoveries in life sciences in general and in drug discovery and devolpment in 
particular.  
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